Fibrocell Science (FCSC) 10-K 13 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Mar. 06, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Entity Registrant Name	Fibrocell Science, Inc.
Entity Central Index Key	357097
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Trading Symbol	FCSC
Document Type	10-K
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		40,856,815
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$64.10

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$37,495	$60,033
Accounts receivable, net of allowance for doubtful accounts of $17 and $5, respectively	4	28
Inventory	571	597
Prepaid expenses and other current assets	1,278	1,202
Total current assets	39,348	61,860
Property and equipment, net	1,598	1,701
Intangible assets, net of accumulated amortization of $1,653 and $1,102, respectively	4,687	5,238
Other assets	1	215
Total assets	45,634	69,014
Current liabilities:
Accounts payable	1,124	2,958
Accrued expenses	1,675	487
Deferred revenue	416	148
Warrant liability, current	278	0
Total current liabilities	3,493	3,593
Warrant liability, long term	11,008	15,216
Other long term liabilities	724	539
Total liabilities	15,225	19,348
Commitments
Stockholders' equity:
Common stock, $0.001 par value; 100,000,000 shares authorized; 40,856,815 and 39,832,225 shares issued and outstanding, respectively	41	40
Additional paid-in capital	143,086	136,694
Accumulated deficit	-112,718	-87,068
Total stockholders’ equity	30,409	49,666
Total liabilities and stockholders’ equity	$45,634	$69,014

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Allowance for doubtful accounts (in dollars)	$17	$5
Intangible assets, net of accumulated amortization (in dollars)	$1,653	$1,102
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	40,856,815	39,832,225
Common stock, shares outstanding	40,856,815	39,832,225

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Revenue from product sales	$180	$200	$153
Cost of sales	2,312	7,501	7,804
Gross loss	-2,132	-7,301	-7,651
Selling, general and administrative expenses	11,623	9,440	11,546
Research and development expenses	16,199	13,762	10,193
Operating loss	-29,954	-30,503	-29,390
Other income (expense):
Warrant revaluation and other finance income (expense)	3,930	-1,053	20,404
Derivative revaluation expense	0	0	-23
Interest income (expense)	6	2	-1,017
Loss on extinguishment of debt	0	0	-5,617
Other income	368	0	0
Loss from continuing operations before income taxes	-25,650	-31,554	-15,643
Deferred tax benefit	0	0	2,500
Loss from continuing operations	-25,650	-31,554	-13,143
Loss from discontinued operations, net of tax	0	0	-11
Gain on sale of discontinued operations, net of tax	0	0	467
Net loss	-25,650	-31,554	-12,687
Net loss attributable to non-controlling interest	0	0	-24
Net loss attributable to Fibrocell Science, Inc. common stockholders	($25,650)	($31,554)	($12,711)
Per Share Information:
Loss from continuing operations - basic	($0.63)	($1.06)	($1.47)
Gain on sale of discontinued operations, net of tax - basic	$0	$0	$0.05
Net loss per common share - basic	($0.63)	($1.06)	($1.42)
Loss from continuing operations - diluted	($0.70)	($1.12)	($2.65)
Gain on sale of discontinued operations, net of tax - diluted	$0	$0	$0.05
Net loss per common share - diluted	($0.70)	($1.12)	($2.60)
Weighted average number of common shares outstanding - Basic (in shares)	40,789,445	29,830,207	8,965,098
Weighted average number of common shares outstanding - Diluted (in shares)	40,969,399	30,196,616	9,147,060

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Deficit) (USD $)	Total	Common Stock	Subscription receivable	Additional paid-in capital	Accumulated deficit	Non-controlling interest
In Thousands, except Share data, unless otherwise specified
Balance at Dec. 31, 2011	($16,268)	$4	($550)	$27,081	($43,271)	$468
Balance (shares) at Dec. 31, 2011		3,827,132
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from equity financing, net	40,185	18	-2,004	42,171
Proceeds from equity financing, net (in shares)		18,203,000
Fair value of warrants issued with financing	1,098			1,098
Preferred stock series D and E converted	1,350	2		1,348
Preferred stock series D and E converted (in shares)		2,021,120
Conversion of notes payable	2,385	1		2,384
Conversion of notes payable (in shares)		898,641
Issuance of common stock	6,917	1		6,916
Issuance of common stock (in shares)		1,317,520
Cancellation of certificate	0		550	-550
Cancellation of certificate (in shares)		-40,000
Exercise of warrants	10			10
Exercise of warrants (in shares)		2,496
Stock-based compensation expense	1,224			1,224
Net loss	-12,711				-12,243	-468
Balance at Dec. 31, 2012	24,190	26	-2,004	81,682	-55,514	0
Balance (shares) at Dec. 31, 2012		26,229,909
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from equity financing, net	47,118	12	0	47,106
Proceeds from equity financing, net (in shares)		12,311,698
Subscription received	2,004		2,004
Issuance of common stock	6,406	2		6,404
Issuance of common stock (in shares)		1,243,781
Exercise of warrants	352			352
Exercise of warrants (in shares)		46,837
Stock-based compensation expense	1,150			1,150
Net loss	-31,554				-31,554
Balance at Dec. 31, 2013	49,666	40	0	136,694	-87,068	0
Balance (shares) at Dec. 31, 2013		39,832,225
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock	5,154	1		5,153
Issuance of common stock (in shares)		1,024,590
Stock-based compensation expense	1,239			1,239
Net loss	-25,650				-25,650
Balance at Dec. 31, 2014	$30,409	$41	$0	$143,086	($112,718)	$0
Balance (shares) at Dec. 31, 2014		40,856,815

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net loss	($25,650)	($31,554)	($12,687)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on extinguishment of debt	0	0	5,617
Gain on sale of Agera	0	0	-467
Stock issued for exclusive channel collaboration agreement	5,154	6,406	6,917
Stock-based compensation expense	1,239	1,150	1,224
Warrant revaluation and other finance (income) expense	-3,930	1,053	-20,404
Derivative revaluation expense	0	0	23
Deferred tax benefit	0	0	-2,500
Loss on disposal of property and equipment	13	5	0
Depreciation and amortization	883	863	821
Provision for doubtful accounts	12	-20	25
Amortization of debt issuance costs	0	0	146
Change in operating assets and liabilities:
Accounts receivable	12	54	-60
Inventory	26	-120	-477
Prepaid expenses	-76	69	-196
Other assets	214	-215	0
Accounts payable	-1,834	2,037	-966
Accrued expenses and other liabilities	1,373	188	407
Deferred revenue	268	9	83
Miscellaneous other	0	0	-81
Net cash used in operating activities	-22,296	-20,075	-22,575
Cash flows from investing activities:
Purchase of property and equipment	-242	-360	-493
Proceeds from the sale of Agera	0	0	1,002
Net cash (used in) provided by investing activities	-242	-360	509
Cash flows from financing activities:
Debt issuance costs	0	0	-46
Net proceeds from preferred stock	0	0	7,864
Net proceeds from common stock	0	47,118	40,185
Subscription received	0	2,004	0
Payments on insurance loan	0	0	-97
Principal payments on note payable	0	0	-4,823
Dividends paid on preferred stock	0	0	-470
Net cash provided by financing activities	0	49,122	42,613
Net (decrease) increase in cash and cash equivalents	-22,538	28,687	20,547
Cash and cash equivalents, beginning of period	60,033	31,346	10,799
Cash and cash equivalents, end of period	$37,495	$60,033	$31,346

Business_and_Organization

Business and Organization	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Business and Organization	Business and Organization
	Fibrocell Science, Inc. (as used herein, “we,” “us,” “our,” “Fibrocell” or the “Company”) is the parent company of Fibrocell Technologies, Inc. (“Fibrocell Tech”) and Fibrocell Science Hong Kong Limited (“Fibrocell Hong Kong”), a company organized under the laws of Hong Kong. Fibrocell Tech is the parent company of Isolagen Europe Limited, a company organized under the laws of the United Kingdom (“Isolagen Europe”), Isolagen Australia Pty Limited, a company organized under the laws of Australia (“Isolagen Australia”), and Isolagen International, S.A., a company organized under the laws of Switzerland (“Isolagen Switzerland”). The Company’s international activities are currently immaterial.
	The Company is an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s lead orphan drug program is in late-stage pre-clinical development for the treatment of RDEB (recessive dystrophic epidermolysis bullosa). The Company’s collaboration with Intrexon Corporation (NYSE:XON) (“Intrexon”), a leader in synthetic biology, includes using genetically-modified autologous fibroblast cells to express target proteins that are inactive or missing from patients with rare genetic skin and connective tissue disorders. The Company is also pursuing medical applications for azficel-T, the Company’s proprietary autologous fibroblast technology, for vocal cord scarring and restrictive burn scarring. Both indications are currently in Phase II clinical trials. The Company’s ongoing scientific research collaboration with the University of California, Los Angeles (“UCLA”) has yielded discoveries and technologies related to stem cells and regenerative cells in human skin. The technologies from this collaboration and the Company’s exclusive license agreements with UCLA enable the Company to expand its proprietary personalized biologics platform which uses human fibroblasts and stem cells from skin to create localized therapies that are compatible with the unique biology of each patient.
	The Company’s securities ceased trading on the NYSE MKT effective at the close of business on August 28, 2014 and commenced trading on NASDAQ on August 29, 2014. The Company’s common stock continues to trade under its current trading symbol “FCSC”.
	The Company previously marketed a skin care line with broad application in core target markets through its consolidated subsidiary, Agera Laboratories, Inc. (“Agera”), which was sold on August 31, 2012.  The Company had owned 57% of the outstanding shares of Agera.  As a result of the sale of Agera, the Company operates in one segment and Agera is classified as discontinued operations.  Please refer to Note 16 for more details.

Basis_of_Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	The prior year financial statements contain certain reclassifications to the results of operations for the years ended December 31, 2013 and 2012 to conform to the presentation for the year ended December 31, 2014 in this Form 10-K. These reclassifications were made in conjunction with the Company’s de-emphasis on its commercial product LAVIV® and towards further research and development of the underlying azficel-T process as well as on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs.
	For the year ended December 31, 2014, amortization expense of approximately $0.6 million was included in research and development expense on the Consolidated Statements of Operations. For the years ended December 31, 2013 and 2012, amortization expense of approximately $0.6 million and $0.6 million, respectively, was reclassed from cost of sales to research and development expense on the Consolidated Statements of Operations to conform to the current presentation. For the year ended December 31, 2014, the Company’s Food and Drug Administration (“FDA”) license fees related to its Biologics License Application (“BLA”) of approximately $0.6 million were included in research and development expense on the Consolidated Statements of Operations. For the years ended December 31, 2013 and 2012, FDA license fees of approximately $0.6 million and $0.6 million, respectively, were reclassed from selling, general and administrative expense to research and development expense on the Consolidated Statements of Operations to conform to the current presentation.
	On April 30, 2013, the Company completed a reverse stock split on the basis of one share of common stock for each currently outstanding 25 shares of pre-split common stock.  All common share and per share data included in these financial statements reflect this reverse stock split.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies
	Use of Estimates
	The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and notes.  In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows.  Actual results may differ materially from those estimates.
	Principles of Consolidation
	These consolidated financial statements include the accounts of Fibrocell and its wholly owned subsidiaries.  All intercompany accounts and transactions have been eliminated in consolidation.
	Cash and Cash Equivalents
	The Company considers highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
	Concentration of Credit Risk
	As of December 31, 2014, the Company maintains its operating cash with one major U.S. domestic bank and the remainder of its cash and cash equivalents as a money market fund with one major global bank.  Federal insurance coverage on our operating cash amounted to $250,000 per depositor at each financial institution, and the Company’s non-interest bearing cash balances may exceed federally insured limits.  The terms of these deposits are on demand to minimize risk.  The Company has not incurred losses related to these deposits.
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable are recorded at the invoiced amount, net of related cash discounts, and do not bear interest.  The Company does not have any off-balance sheet exposure related to the Company’s customers.  The Company maintains an allowance for doubtful accounts related to its accounts receivable that have been deemed to have a high risk of collectability.  Management reviews its accounts receivable on a monthly basis to determine if any receivables will potentially be uncollectible.  Management analyzes historical collection trends and changes in its customer payment patterns, customer concentration and creditworthiness when evaluating the adequacy of its allowance for doubtful accounts.  In its overall allowance for doubtful accounts, the Company includes any receivable balances that are determined to be uncollectible.  Based on the information available, management believes the allowance for doubtful accounts is adequate; however, actual write-offs might exceed the recorded allowance.
	The following table summarizes the changes in the allowance for doubtful accounts receivable for the indicated periods:
			Balance at beginning of year			Additions charged to earnings			Uncollectible receivables written off, net of recoveries			Balance at end of year
	31-Dec-14		5			12			(2	)		17
	31-Dec-13		25			(20	)		—			5
	31-Dec-12		—			25			—			25
	Inventory
	Inventories are determined at the lower of cost or market value, with cost determined under specific identification and on the first-in-first-out method.  Inventories consist of raw materials and work-in-process.
	Property and Equipment
	Property and equipment is carried at acquisition cost less accumulated depreciation. Depreciation is computed on a straight-line basis over the estimated useful life of the asset. The cost of repairs and maintenance is charged to expense as incurred. As of December 31, 2013, the useful life for all property and equipment was three years, except for leasehold improvements which were depreciated over the remaining lease term or the life of the asset, whichever was shorter. In the first quarter of 2014, the Company adjusted its useful lives to reflect the expected consumption of the economic benefit of these assets as noted in the following table:
	Property and equipment category		Useful life
	Laboratory equipment		6 years
	Computer equipment and software		3 years
	Furniture and fixtures		10 years
	Leasehold improvements		Lesser of remaining lease term or life of asset
	In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) ASC Topic 250 Accounting Changes and Error Corrections, the Company accounted for this change in useful lives as a change in estimate, with prospective application only. The impact of this change in estimate on depreciation expense was immaterial to the results on the Consolidated Statements of Operations.
	Intangible Assets
	Intangible assets are research and development assets related to the Company’s primary study on azficel-T that was recognized upon emergence from bankruptcy. The portion of the reorganization value which was attributed to identified intangible assets was $6.3 million. Effective January 1, 2012, the Company launched LAVIV® and as a result, the research and development intangible assets related to the Company’s primary study are considered finite-lived intangible assets and are being amortized over 12 years.  For each of the years ended December 31, 2014, 2013 and 2012, amortization expense was approximately $0.6 million.  The Company expects to amortize approximately $0.6 million for each of the next five years.
	Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges.  Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis.  In accordance with Financial Accounting Standards Board Accounting Standard Codification (“ASC”) 360-10-35 Impairment or Disposal of Long-Lived Assets, the Company reviews its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  There was no impairment expense recognized for the years ended December 31, 2014, 2013 or 2012.
	Warrant Liability
	The Company accounts for stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement.  Stock warrants are accounted for as a derivative in accordance with Accounting Standards Codification 815, Derivatives and Hedging (“ASC 815”) if the stock warrants contain “down-round protection” or other terms that could potentially require “net cash settlement” and therefore, do not meet the scope exception for treatment as a derivative.  Since “down-round protection” is not an input into the calculation of the fair value of the warrants, the warrants cannot be considered indexed to the Company’s own stock which is a requirement for the scope exception as outlined under ASC 815.  Warrant instruments that could potentially require “net cash settlement” in the absence of express language precluding such settlement and those which include “down-round provisions” are initially classified as derivative liabilities at their estimated fair values, regardless of the likelihood that such instruments will ever be settled in cash.  The Company will continue to classify the fair value of the warrants that contain “down-round protection” and “net cash settlement” as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability.  For additional discussion on warrants, see Note 7.
	Revenue Recognition
	The Company recognizes revenue over the period LAVIV® is shipped for injection in accordance with ASC 605 Revenue Recognition (“ASC 605”).  In general, ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services rendered, (3) the fee is fixed and determinable and (4) collectability is reasonably assured.  Revenue from the sale of LAVIV® is not recognized until the first shipment for an injection is shipped.
	Cost of Sales
	Cost of sales includes the costs related to the processing of cells for LAVIV®, including direct and indirect costs. Beginning in 2014, cost of sales is accounted for using a standard cost system which allocates the direct costs associated with the Company’s manufacturing, facility, quality control, and quality assurance operations as well as overhead costs. The principal reason for the relatively small level of revenue as compared to the cost of sales is that the Company changed corporate strategy in late 2013 to de-emphasize sales of LAVIV® into the aesthetic markets, and towards further research and development of the underlying azficel-T process as well as on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs.
	Research and Development Expenses
	Research and development costs are expensed as incurred and include salaries and benefits, costs paid to third party contractors to perform research, conduct clinical trials, develop and manufacture drug materials and delivery devices, and a portion of facilities cost. Research and development costs also include costs to manufacture product for clinical trial use and to develop manufacturing, cell collection and logistical process improvements.
	Clinical trial costs are a significant component of research and development expenses and include costs associated with third party contractors. Invoicing from third party contractors for services performed can lag several months. The Company accrues the costs of services rendered in connection with third party contractor activities based on its estimate of management fees, site management and monitoring costs and data management costs.
	Stock-based Compensation
	The Company accounts for stock-based awards to employees using the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation.  In addition, the Company accounts for stock-based compensation to nonemployees in accordance with the accounting guidance for equity instruments that are issued to other than employees.  The Company uses a Black-Scholes option-pricing model to determine the fair value of each option grant as of the date of grant for expense incurred.  The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, expected stock price volatility and expected life of the options.  Expected stock price volatility is based on historical volatility of the Company’s stock and the stock of the Company’s peer companies.  The risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant.  The expected life for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted.  The Company estimates future forfeitures of options based upon expected forfeiture rates.
	Income Taxes
	An asset and liability approach is used for financial accounting and reporting for income taxes. Deferred income taxes arise from temporary differences between income tax and financial reporting and principally relate to recognition of revenue and expenses in different periods for financial and tax accounting purposes and are measured using currently enacted tax rates and laws.  In addition, a deferred tax asset can be generated by net operating loss (NOLs) carryover.  If it is more likely than not that some portion or all of a deferred tax asset will not be realized, a valuation allowance is recognized.
	In the event the Company is charged interest or penalties related to income tax matters, the Company would record such interest as interest expense and would record such penalties as other expense in the consolidated statements of operations.  No such charges have been incurred by the Company.  For each of the years ended December 31, 2014, 2013 and 2012, the Company had no uncertain tax positions.
	At December 31, 2014, and December 31, 2013, the Company has provided a full valuation allowance for the net deferred tax assets, the large majority of which relates to the future benefit of loss carryovers.  The tax years 2011 through the present remain open to examination by the major taxing jurisdictions to which the Company is subject.
	Loss Per Share Data
	Basic loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during a period.  The diluted loss per share calculation gives effect to dilutive options, warrants, convertible notes, convertible preferred stock, and other potential dilutive common stock including selected restricted shares of common stock outstanding during the period.  Diluted loss per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and warrants, assuming the exercise of all in-the-money stock options and warrants.  Common share equivalents have been excluded where their inclusion would be anti-dilutive.
		For the Twelve Months Ended December 31,
	($ in thousands except share and per share data)	2014				2013				2012
	Loss per share — Basic:
	Numerator for basic loss per share	$	(25,650	)		$	(31,554	)		$	(12,711	)
	Denominator for basic loss per share	40,789,445				29,830,207				8,965,098
	Basic loss per common share	$	(0.63	)		$	(1.06	)		$	(1.42	)
	Loss per share — Diluted:
	Numerator for basic loss per share	$	(25,650	)		$	(31,554	)		$	(12,711	)
	Adjust: Fair value of dilutive warrants outstanding	2,840				2,270				11,091
	Numerator for diluted loss per share	$	(28,490	)		$	(33,824	)		$	(23,802	)
	Denominator for basic loss per share	40,789,445				29,830,207				8,965,098
	Plus: Incremental shares underlying “in the money” warrants outstanding	179,954				366,409				181,962
	Denominator for diluted loss per share	40,969,399				30,196,616				9,147,060
	Diluted loss per common share	$	(0.70	)		$	(1.12	)		$	(2.60	)
	The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding, as their effect would be anti-dilutive:
		For the Twelve Months Ended December 31,
		2014			2013			2012
	Shares underlying “out of the money” options outstanding	2,086,450			1,070,720			562,025
Shares underlying “in the money” options outstanding	—			998,000			—
Shares underlying “out of the money” warrants outstanding	4,831,352			4,831,352			4,845,352
Shares underlying “in the money” warrants outstanding	—			—			1,320
Fair Value of Financial Instruments
The carrying values of certain of the Company’s financial instruments, including cash equivalents and accounts payable approximates fair value due to their short maturities.  Warrant liability is also recorded at fair value. The fair values of the Company’s long term obligations are based on assumptions concerning the amount and timing of estimated future cash flows and assumed discount rates reflecting varying degrees of risk.  The carrying values of the Company’s long term obligations approximate their fair values.
Recently Issued Accounting Pronouncements
In January 2015, the FASB issued ASU No. 2015-01, "Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items", which eliminates from U.S. GAAP the concept of extraordinary items. The pronouncement is effective for annual reporting periods ending after December 15, 2015 with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial statements.
In August 2014, the FASB issued ASU No. 2014-15, "Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern", which defines management’s responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provided related footnote disclosures. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The adoption of this guidance will require the Company to disclose its evaluation of its ability to continue as a going concern in the footnotes to the financial statements.
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” which supersedes the current revenue recognition requirements under ASC Topic 605, “Revenue Recognition”. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. It also provides a five step approach to achieve this principle. For public entities, the new guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. Based on current operating conditions, the adoption of this guidance does not have a material impact on the Company’s financial statements; however, it may have a material impact in the future.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory	Inventory
	Inventories consisted of the following as of:
	($ in thousands)	December 31,		December 31,
		2014		2013
	Raw materials	$	357	$	511
	Work-in-process	214		86
	Inventory	$	571	$	597

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment
	Property and equipment consisted of the following as of:
	($ in thousands)	December 31,			December 31,
		2014			2013
	Laboratory equipment	$	1,279		$	1,045
	Computer equipment and software	206			179
	Furniture and fixtures	49			15
	Leasehold improvements	772			448
	Construction-in-process	343			749
		2,649			2,436
	Less: Accumulated depreciation	(1,051		)	(735		)
	Property and equipment, net	$	1,598		$	1,701
	Depreciation expense was approximately $0.3 million, $0.3 million and $0.3 million for the years ended December 31, 2014, 2013 and 2012, respectively.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses
	Accrued expenses consisted of the following as of:
	($ in thousands)	December 31,		December 31,
		2014		2013
	Accrued professional fees	$	881	$	194
	Accrued compensation	540		40
	Accrued other	254		253
	Accrued expenses	$	1,675	$	487

Warrants

Warrants	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Warrants Disclosure [Text Block]	Warrants
	The Company accounts for stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement.  Stock warrants are accounted for as a derivative in accordance with Accounting Standards Codification 815, Derivatives and Hedging (“ASC 815”) if the stock warrants contain “down-round protection” or other terms that could potentially require “net cash settlement” and therefore, do not meet the scope exception for treatment as a derivative.  Since “down-round protection” is not an input into the calculation of the fair value of the warrants, the warrants cannot be considered indexed to the Company’s own stock which is a requirement for the scope exception as outlined under ASC 815.  Warrant instruments that could potentially require “net cash settlement” in the absence of express language precluding such settlement and those which include “down-round provisions” are initially classified as derivative liabilities at their estimated fair values, regardless of the likelihood that such instruments will ever be settled in cash.  The Company will continue to classify the fair value of the warrants that contain “down-round protection” and “net cash settlement” as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability.
	The following table summarizes outstanding liability classified warrants to purchase common stock as of:
		Number of Warrants
		31-Dec-14			31-Dec-13			Exercise				Expiration Dates
								Price
	Issued in Series A, B and D Preferred Stock offering	2,247,118			2,247,118			$	6.25			Oct 2015 - Dec 2016
	Issued in March 2010 financing	393,416			393,416			$	6.25			Mar 1, 2016
	Issued in June 2011 financing	6,113			6,113			$	22.5			Jun 1, 2016
	Issued in August 2011 financing	565,759			565,759			$	18.75			Aug 1, 2016
	Issued to placement agents in August 2011 financing	50,123			50,123			$	13.635			Aug 1, 2016
	Issued in Series B, D and E Preferred Stock offerings	76,120			76,120			$	2.5			Nov 2015 - Dec 2017
	Issued with Convertible Notes	1,125,578			1,125,578			$	2.5			Jun 1, 2018
	Issued in Series E Preferred Stock offering	1,568,823			1,568,823			$	7.5			Dec 1, 2018
	Total	6,033,050			6,033,050
	There were no exercises of warrants during the year ended December 31, 2014. There were 85,000 warrants exercised on a cashless basis resulting in the issuance of 46,837 shares of common stock for the year ended December 31, 2013.
	Liability-classified Warrants
	The foregoing warrants are recorded as liabilities at their estimated fair value at the date of issuance, with the subsequent changes in estimated fair value recorded in other income (expense) in the Company’s statement of operations in each subsequent period.  The change in the estimated fair value of our warrant liability for the years ended December 31, 2014, 2013 and 2012 resulted in non-cash income of $3.9 million, non-cash expense of $1.1 million, and non-cash income of $20.4 million, respectively.  The Company utilizes the Monte Carlo simulation valuation method to value the liability classified warrants.
	The estimated fair value of these warrants is determined using Level 3 inputs.  Inherent in the Monte Carlo valuation model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield.  The Company estimates the volatility of its common stock based on historical volatility that matches the expected remaining life of the warrants.  The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants.  The expected life of the warrants is assumed to be equivalent to their remaining contractual term.  The dividend rate is based on the historical rate, which the Company anticipates to remain at zero.
	The following table summarizes the calculated aggregate fair values, along with the assumptions utilized in each calculation:
	($ in thousands, except per share data)	December 31,				December 31,				December 31,
		2014				2013				2012
	Calculated aggregate value	11,281				15,216				14,515
	Weighted average exercise price per share of warrant	7.08				7.08				7.04
	Closing price per share of common stock	$	2.59			$	4.06			$	3.75
	Volatility	68		%		70		%		65		%
	Weighted average remaining expected life (years)	2 years, 7 months				3 years, 6 months				4 years, 6 months
	Risk-free interest rate	0.86		%		1.2		%		0.6		%
	Dividend yield	—		%		—		%		—		%

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt	Debt
	Convertible Note Payable
	On June 1, 2012, the Company entered into an exchange agreement with existing note holders pursuant to which the Company agreed to repay half of each holder’s 12.5% promissory notes due June 1, 2012 (the "Notes"  and exchange the balance of each holder’s original note, for (i) a new 12.5% note (the “Convertible Notes”) with a principal amount equal to such balance, and (ii) a five-year warrant (“Warrant”) to purchase a number of shares of common stock equal to the number of shares of common stock underlying such note on the date of issuance.  Details of Notes are as follows:
	•	The Notes accrued interest at a rate of 12.5% per annum payable quarterly in cash or, at the Company’s option, 15% per annum payable in kind by capitalizing such unpaid amount and adding it to the principal as of the date it was due.
	•	The maturity date of the Notes was September 1, 2013, provided that the Holders may require the Company to redeem 25% of the principal amount of the Notes on each of December 1, 2012, March 1, 2013, June 1, 2012 and September 1, 2013.
	•	To the extent that Holders of the Notes converted any portion of the Notes prior to any such redemption date, the amount of all future redemption payments will be reduced by such converted amount on a pro rata basis over the remaining redemption dates.
	•	The Notes were convertible at a conversion price of $6.25 per share, provided that, with certain exceptions, if, at any time while the Notes are outstanding, the Company issues any Company common stock or common stock equivalents at an effective price per share that is lower than the then the conversion price of the Notes, then the conversion price of the Notes will be reduced to equal the lower price.
	•	The Notes may be accelerated if any events of default occur, which include, in addition to certain customary default provisions, if at any time on or after October 1, 2012 the Company fails to have reserved, for conversion of the Notes and exercise of the Warrants, a sufficient number of available authorized but unissued shares of common stock.
	The Notes were converted at a conversion price of $6.25 per share.  To the extent that holders of the Notes converted any portion of the Notes prior to any such redemption date, the amount of all future redemption payments was reduced by such converted amount on a pro rata basis over the remaining redemption dates.  The Notes were extinguished in October 2012 through partial conversions into common stock and partial repayments in cash.
	Loss on Extinguishment of Debt
	As a result of the June 1, 2012 debt exchange as discussed above, the Company recorded a loss on extinguishment of the 12.5% promissory note of $5.6 million in the consolidated statement of operations for the year ended December 31, 2012 due to the significant modification of the original debt.  The details of the loss included recording the fair value of the embedded conversion option of $1.2 million and the fair value of liability-classified warrants of $4.4 million.  See Note 7 for further discussion of the warrant liability.

Equity

Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Equity	Equity
	Common stock
	In October of 2012, the Company closed a private placement transaction (the “Offering”) with certain accredited investors pursuant to which the Company sold securities consisting of 18,000,000 shares of common stock at a purchase price of $2.50 per share.  An additional 203,000 shares were given to placement agents in connection with the Offering.  The Company received net proceeds of $40.2 million, incurred $2.7 million in offering costs and had a subscription receivable of $2.0 million which was subsequently collected in July of 2013.
	In connection with the execution of the exclusive channel collaboration (the “Channel Agreement”) on October 5, 2012, the Company entered into a Stock Issuance Agreement with Intrexon Corporation ("Intrexon"), who is an affiliate of NRM VII Holdings I, LLC, the Company’s largest shareholder. The Company agreed to issue to Intrexon a number of shares of Company common stock based on a per share value of the price at which the Company sold shares of common stock in the Offering (the “Technology Access Shares”).  The closing took place on October 9, 2012.  The Company recorded a fair value of $6.9 million for 1,317,520 shares, on a per share value of $5.25 based on the closing price of the Company’s common stock on the closing date, issued to Intrexon for the closing of the Stock Issuance Agreement as a research and development expense in the fourth quarter of 2012.  In connection with the issuance of the Technology Access Shares, Intrexon became a party to a Registration Rights Agreement, which provides Intrexon with a demand registration right with respect to the resale of the Technology Access Shares.  See Note 13 for further discussion on the collaboration with Intrexon.
	On October 5, 2012, the Company entered into an amendment and conversion agreement (the “Debt Agreement”) with the holders of its 12.5% Convertible Notes in the aggregate original principal amount of approximately $3.5 million.  Pursuant to the Debt Agreement, the Company and the Note holders agreed that the Company would repay approximately $1.7 million of the Notes in cash (representing approximately $1.5 million in principal and $0.2 million in unpaid interest), and the remaining Notes (representing approximately $2.1 million in principal and $0.3 million in unpaid interest) would be converted into shares of common stock at a conversion price of $2.50 per share.  The total number of shares of common stock issued upon the conversion of the Notes was 861,970 shares. There were conversions of notes into 36,671 common shares before the Offering.
	Effective upon the completion of the Offering, the Company entered into warrant modification agreements with the holders of warrants to purchase 4,209,357 shares of common stock at exercise prices of between $6.25 per share and $7.50 per share pursuant to which the parties agreed, among other items: (a) to extend the expiration date of the warrants by one year; and (b) to delete the full-ratchet anti-dilution adjustment provisions contained in the warrants (including with respect to the Offering discussed above). As such, the exercise price and number of shares underlying the foregoing warrants were not modified due to the completion of the Offering.
	In connection with the execution of the first amendment to the exclusive channel collaboration agreement (the “Amendment”) on June 28, 2013, the Company entered into a Supplemental Stock Issuance Agreement with Intrexon.  The Company agreed to issue to Intrexon a number of shares of Company common stock based on a per share value of the closing price of the Company’s common stock on the NYSE MKT on the day prior to execution of the Supplemental Stock Issuance Agreement (the “Supplemental Access Fee Shares”).  The Supplemental Access Fee Shares were issued upon the satisfaction of customary closing conditions, including the approval for the listing of the Supplemental Access Fee Shares on the NYSE MKT.  The closing took place on July 26, 2013.  The Company recorded a fair value of $6.4 million for 1,243,781 shares, on a per share value of $5.15 based on the closing price of the Company’s common stock on the closing date, issued to Intrexon for the closing of the Supplemental Stock Issuance Agreement as a research and development expense in the third quarter of 2013.  See Note 13 for further discussion on the collaboration with Intrexon.
	In October of 2013, the Company completed an underwritten public offering of 11,000,000 shares of common stock at a public offering price of $4.10 per share.  The net proceeds to the Company, after underwriting discounts and commissions and estimated offering expenses, were approximately $42.1 million.  The underwriters for the public offering of common stock partially exercised their over-allotment option to purchase an additional 1,311,698 shares of common stock at a public offering price of $4.10 per share.  The partial exercise of the over-allotment option increased the aggregate net proceeds to the company, after underwriting discounts and commissions and estimated offering expenses, from approximately $42.1 million to approximately $47.1 million.
	In connection with the execution of the second amendment to the exclusive channel collaboration agreement (the “Second Amendment”) on January 10, 2014 between the Company and Intrexon, the Company entered into a Supplemental Stock Issuance Agreement with Intrexon. The Company agreed to issue to Intrexon a number of shares of Company common stock based on a per share value of the closing price of the Company’s common stock on the NYSE MKT on the day prior to execution of the Supplemental Stock Issuance Agreement (the “Supplemental Access Fee Shares”). The Supplemental Access Fee Shares were issued upon the satisfaction of customary closing conditions, including the approval for the listing of the Supplemental Access Fee Shares on the NYSE MKT. The closing took place on January 24, 2014. The Company recorded a research and development expense in the first quarter of 2014 for the 1,024,590 shares issued to Intrexon as a technology access fee. The shares were issued based on a per share value of $5.03 based on the closing price of the Company’s common stock on the closing date, totaling approximately $5.2 million, which was recorded as Research and development expenses. For additional discussion on the Company’s collaboration with Intrexon, see Note 13.
	Preferred Stock
	The Company is authorized to issue 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of the Company’s preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change of control of the Company or other corporate action. There were no preferred shares issued or outstanding as of December 31, 2014 or December 31, 2013.
	Redeemable Preferred stock
	On October 5, 2012, upon the approval of the requisite number of holders of the Company’s Series D 6% Cumulative Perpetual Convertible Preferred Stock (the “Series D Preferred Stock”) and Series E 8% Cumulative Convertible Preferred Stock (the “Series E Preferred Stock”), the Company filed amendments, effective on such date, to each of the Certificates of Designation for the Preferred Stock providing that if the Company completed an equity financing pursuant to which the Company received gross proceeds of no less than $35.0 million (a “Qualified Financing”), then immediately prior to the closing of such Qualified Financing each outstanding share of preferred stock shall be automatically converted into that number of shares of common stock determined by dividing the stated value of such share of Series D and Series E preferred stock by $6.25. The Offering discussed above was a Qualified Financing, and as such, the Series D and E preferred stock was automatically converted into 1,917,120 shares of common stock upon completion of the Offering, 454,560 of which were Series D and 1,462,560 of which were Series E. There were 104,000 common shares issued as a result of conversion of Series D preferred shares during 2012 before the automatic conversion of the preferred shares pursuant to the Offering.  As of the closing of the Offering, the Company had no shares of preferred stock outstanding
	The following table shows the activity of Series D and Series E Redeemable Preferred stock, with a par value of $0.001 per share and a stated value of $25,000 per share:
		Series D		Series E		Total
		Preferred		Preferred
	Balance at December 31, 2011	3,641		—		3,641
	Issuance of Series E Preferred stock	—		9,141		9,141
	Series D and Series E Preferred converted to common stock	(3,641	)	(9,141	)	(12,782	)
	Balance at December 31, 2012	—		—		—
	During May, June and July 2012 the Company sold to accredited investors in a private placement Series E Convertible Preferred Stock as follows:
	Date of financing	# of shares		Net Proceeds			Warrant		# of Warrants
		of Series E		($ in 000’s)			Exercise		Issued
		Preferred					Price
	14-May-12	3,353		$	2,843		$	7.5	590,128
	24-May-12	2,364		2,042			7.5		416,064
	2-Jun-12	945		822			7.5		166,320
	7-Jun-12	1,192		1,037			7.5		209,792
	28-Jun-12	507		441			7.5		89,232
	16-Jul-12	780		679			7.5		137,280
		9,141		$	7,864				1,608,816
	As a result of the May, June and July 2012 private placement Series E Convertible Preferred Stock transaction, the net proceeds of $7.8 million were allocated to the fair value of the warrants upon issuance. The July 16, 2012 sale represented the final closing of the Offering and effective on such date, the Company closed the Offering.
	Conversion option of Convertible Note Payable
	In connection with the issuance of the June 1, 2012 Convertible Notes, an embedded conversion option was recorded as a derivative liability under ASC 815, Derivatives and Hedging, in the 2012 consolidated balance sheet until October 2012 when the notes were converted to common stock. The derivative liability was re-measured on the Company’s reporting dates until October 9, 2012 when the Notes were converted into common stock resulting in revaluation expense of less than $0.1 million for the year ended December 31, 2012 in our statement of operations. The fair value of the derivative liability was determined using the Black-Scholes option-pricing model and is affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. The Convertible Notes were reclassified to equity which amounted to $2.4 million.
	Conversion option of Redeemable Preferred stock
	The embedded conversion option for the Series D Preferred was recorded as a derivative liability under ASC 815 in the consolidated balance sheet until its conversion to common stock in 2012. The fair value of the derivative liability was determined using the Black-Scholes option-pricing model and is affected by changes in inputs to that model including the Company’s stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. The derivative liability was re-measured resulting in income of $0.1 million for the year ended December 31, 2012 in the Company’s Consolidated Statement of Operations until the preferred stock was converted on October 9, 2012 into common stock and $1.4 million was recorded in equity.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements
	The Company adopted the accounting guidance on fair value measurements for financial assets and liabilities measured on a recurring basis.  The guidance requires fair value measurements be classified and disclosed in one of the following three categories:
	•	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	•	Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;
	•	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
	The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liability measured at fair value on a recurring basis as of December 31, 2014 and 2013:
		Fair value measurement using
	($ in thousands)	Quoted prices in			Significant		Significant		Total
		active markets			other		unobservable
		(Level 1)			observable		inputs
					inputs (Level 2)		(Level 3)
	Balance at December 31, 2014
	Assets:
	Cash and cash equivalents	$	37,495		$	—	$	—	$	37,495
	Liabilities:
	Warrant liability	$	—		$	—	$	11,286	$	11,286
		Fair value measurement using
	($ in thousands)	Quoted prices in			Significant		Significant		Total
		active markets			other		unobservable
		(Level 1)			observable		inputs
					inputs (Level 2)		(Level 3)
	Balance at December 31, 2013
	Assets:
	Cash and cash equivalents	$	60,033		$	—	$	—	$	60,033
	Liabilities:
	Warrant liability	$	—		$	—	$	15,216	$	15,216
	The reconciliation of warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows:
	($ in thousands)	Warrant Liability
	Balance at December 31, 2011	$	23,754
	Issuance of additional warrants	6,766
	Exercise of warrants	(11		)
	Extinguishment of debt related to warrants	4,410
	Change in fair value of warrant liability	(20,404		)
	Balance at December 31, 2012	$	14,515
	Exercise of warrants	(352		)
	Cancellation of warrants	(41		)
	Change in fair value of warrant liability	1,094
	Balance at December 31, 2013	$	15,216
	Exercise of warrants	—
	Cancellation of warrants	—
	Change in fair value of warrant liability	(3,930		)
	Balance at December 31, 2014	$	11,286
	The fair value of the warrant liability is based on Level 3 inputs.  For this liability, the Company developed its own assumptions that do not have observable inputs or available market data to support the fair value.  See Note 7 for further discussion of the warrant liability.
	The reconciliation of derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows:
		Derivative
		Liability
	Balance at January 1, 2012	534
	Issuance of additional preferred stock and other	793
	Conversion of preferred stock	(1,350	)
	Change in fair value of derivative liability	23
	Balance at December 31, 2012	—
	The fair value of the derivative liability is based on Level 3 inputs. For this liability, the Company developed its own assumptions that do not have observable inputs or available market data to support the fair value.

ShareBased_Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation
	Our board of directors (the “Board”) adopted the 2009 Equity Incentive Plan (as amended to date, the “Plan”) effective September 3, 2009.  The Plan is intended to further align the interests of the Company and its stockholders with its employees, including its officers, non-employee directors, consultants and advisors by providing incentives for such persons to exert maximum efforts for the success of the Company.  The Plan allows for the issuance of up to 5,600,000 shares of the Company’s common stock.  In addition, there were 206,000 options issued outside of the Plan to consultants.
	The types of awards that may be granted under the Plan include options (both nonqualified stock options and incentive stock options), stock appreciation rights, stock awards, stock units, and other share-based awards.  The term of each award is determined by the Board at the time each award is granted, provided that the terms of options may not exceed ten years.  Vesting schedules for the stock options vary, but generally vest 25% per year, over four years .  The Plan had 3,530,553 options available for grant as of December 31, 2014.
	Total stock-based compensation expense recognized using the straight-line attribution method in the consolidated statement of operations for the years ended December 31 is as follows:
	($ in thousands)	2014			2013				2012
	Stock option compensation expense for employees and directors	$	1,236		$	1,045			$	1,200
	Equity awards for nonemployees issued for services	3			105				24
	Total stock-based compensation expense	$	1,239		$	1,150			$	1,224
	During the years ended December 31, 2014, 2013 and 2012, the weighted average fair market value using the Black-Scholes option-pricing model of the options granted was $2.64, $2.79 and $5.00, respectively.
	The fair market value of the stock options at the date of grant was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions for the years ended December 31:
		2014		2013			2012
	Expected life	5 years, 11 months		5 years, 7 months			5 years, 8 months
	Interest rate	1.9	%	1.6	%		1.6	%
	Dividend yield	—		—			—
	Volatility	70	%	71	%		64	%
		Number of shares		Weighted-				Weighted-		Aggregate
				average				average		intrinsic
				exercise				remaining		value
				price				contractual term
								(in years)
	Outstanding at December 31, 2011	544,340		$	19.25			7 years, 6 months		$	—
	Granted	38,000		$	8.02
	Forfeited	(20,315	)	$	15.48
	Outstanding at December 31, 2012	562,025		$	18.56			7 years		$	—
	Granted	1,532,000		$	4.15
	Forfeited	(25,305	)	$	14.71
	Outstanding at December 31, 2013	2,068,720		$	7.93			8 years, 5 months		$	544
	Granted	348,000		$	4.19
	Expired	(51,637	)	$	21.61
	Forfeited	(278,633	)	$	4.45
	Outstanding at December 31, 2014	2,086,450		$	7.43			7 years, 2 months		$	—
	Exercisable at December 31, 2014	1,100,250		$	10.63			7 years, 2 months		$	—
	The total fair value of shares vested during the years ended December 31, 2014, 2013 and 2012 was $1.2 million, $1.2 million, and $1.3 million, respectively.  There were no exercises of vested stock options during the years ended 2014, 2013 and 2012.  As of December 31, 2014, there was $2.1 million of total unrecognized compensation cost, related to nonvested stock options which vest over time.  That cost is expected to be recognized over a weighted-average period of 3.8 years.  As of December 31, 2014, there were 986,200 nonvested stock options, with a weighted average exercise price of $3.86 and an average intrinsic value of $0. As of December 31, 2014, there was no unrecognized compensation cost related to performance-based nonvested consultant options.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Note 12. Income Taxes
	Fibrocell Science, Inc. and Fibrocell Technologies, Inc. file a consolidated U.S. Federal income tax return, and file U.S. state income tax returns in several jurisdictions as well. In general, the U.S. federal and state income tax returns remain open to examination by taxing authorities for tax years beginning in 2011 to present. However, if and when the Company claims net operating loss (“NOL”) carryforwards from years prior to 2011 against future taxable income, those losses may be examined by the taxing authorities as well. The Company's foreign subsidiaries file income tax returns in their respective jurisdictions.
	The components of the income tax expense/(benefit) related to continuing operations, are as follows:
		Year ended December 31,			Year ended December 31,			Year ended December 31,
	($ in thousands)	2014			2013			2012
	U.S. Federal:
	Current	$	—		$	—		$	—
	Deferred	—			—			(2,068		)
	U.S. State:
	Current	—			—			—
	Deferred	—			—			(432		)
		$	—		$	—		$	(2,500	)
	The reconciliation between income taxes/(benefit) at the U.S. federal statutory rate and the amount recorded in the accompanying consolidated financial statements is as follows:
		Year ended December 31,			Year ended December 31,			Year ended December 31,
	($ in thousands)	2014			2013			2012
	Tax benefit at U.S. federal statutory rate	$	(8,977	)	$	(11,044	)	$	(5,475	)
	Increase in domestic valuation allowance	11,109			11,626			11,127
	State income taxes/(benefit) before valuation allowance, net of federal benefit	(846		)	(1,026		)	(1,971		)
	Capital loss limitation	—			—			(817		)
	Loss on extinguishment of debt	—			—			1,966
	Derivative revaluation expense	—			—			8
	Warrant revaluation and other finance (income)/expense	(1,375		)	369			(7,141		)
	Other	89			75			(197		)
		$	—		$	—		$	(2,500	)
	The components of the Company’s net deferred tax assets and liabilities at December 31, 2014, 2013 and 2012 are as follows:
	($ in thousands)	31-Dec-14			31-Dec-13			31-Dec-12
	Deferred tax liabilities:
	Intangible assets	$	2,001		$	2,247		$	2,282
	Total deferred tax liabilities	$	2,001		$	2,247		$	2,282
	Deferred tax assets:
	Loss carryforwards	$	63,560		$	54,253		$	49,598
	Capital loss carryforward	841			844			817
	Property and equipment	1,135			1,149			1,327
	License fees	7,055			5,393			—
	Accrued expenses and other	602			412			360
	Stock compensation	2,953			2,698			2,492
	Total deferred tax assets	76,146			64,749			54,594
	Less: valuation allowance	(74,145		)	(62,502		)	(52,312		)
	Total deferred tax assets	$	2,001		$	2,247		$	2,282
	Net deferred tax assets	$	—		$	—		$	—
	As of December 31, 2014, the Company had generated U.S. net operating loss carryforwards of approximately $167.5 million which expire from 2018 to 2034. The NOL carryforwards are available to reduce future taxable income.  However, the NOL carryforwards become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, as well as similar state tax provisions. This could limit the amount of NOLs that we can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of our company immediately prior to an ownership change. Subsequent ownership changes may further affect the limitation in future years. Additionally, U.S. tax laws limit the time during which these carryforwards may be applied against future taxes, therefore, we may not be able to take full advantage of these carryforwards for federal income tax purposes. In addition, the Company has NOL carryforwards in certain non-US jurisdictions of approximately $25.5 million. However, it is not expected that these non-U.S. loss carryforwards will ever be utilized, so they are not included in the components of deferred taxes listed above. The Company does not plan to have material operations in the non-U.S. jurisdictions in the foreseeable future, and does not know when or if income will ever be generated in these foreign jurisdictions. Finally, there are no unremitted earnings in foreign jurisdictions, so no provision for taxes thereupon is required.
	As the Company has had cumulative losses and there is no assurance of future taxable income, valuation allowances have been recorded to fully offset the deferred tax asset at December 31, 2014, 2013, and 2012.  The valuation allowance increased by $11.6 million, $10.2 million, and $11.1 million during 2014, 2013, and 2012, respectively, primarily due to the impact from the current year net losses incurred.

Collaboration_with_Related_Par

Collaboration with Related Party	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
Collaboration with Related Party	Collaboration with Related Party
	Intrexon is an affiliate of our largest shareholder, NRM VII Holdings I, LLC.  In addition, two of our seven directors are also affiliates of NRM VII Holdings I, LLC.
	On October 5, 2012, the Company entered into a Channel Agreement with Intrexon that governs a “channel collaboration” arrangement. The Channel Agreement grants the Company an exclusive license to use proprietary technologies and other intellectual property of Intrexon to develop and commercialize certain products in the United States.  Through the original collaboration with Intrexon, the Company is exploring the use of gene therapy applied to fibroblast cells to treat patients with collagen deficient diseases. The Company is working to apply gene therapy to fibroblasts with the gene to produce collagen VII to treat patients with recessive dystrophic epidermolysis bullosa (“RDEB”). This development concept utilizes applying gene therapy to fibroblasts to up-regulate and produce collagen VII in a controlled manner for localized or systematic treatment of RDEB.
	In connection with the execution of the Channel Agreement on October 5, 2012, the Company entered into a Stock Issuance Agreement with Intrexon.  In connection with the stock issuance, Intrexon became a party to the Registration Rights Agreement, which provides Intrexon with a demand registration right with respect to the resale of the Technology Access Shares.  For additional details see Note 9.
	On June 28, 2013, the Company and Intrexon entered into a First Amendment to the parties’ Channel Agreement.  The Amendment broadens the existing collaboration to include potential treatments based on engineered autologous fibroblast cells for the localized treatment of autoimmune and inflammatory disorders including morphea profunda / linear scleroderma, cutaneous eosinophilias and moderate to severe psoriasis.  In connection with the execution of the First amendment to the Channel Agreement on June 28, 2013, the Company entered into a Supplemental Stock Issuance Agreement with Intrexon. For additional details see Note 9.
	On January 10, 2014, the Company and Intrexon entered into a Second Amendment to the parties’ Exclusive Channel Collaboration Agreement dated October 5, 2012, as previously amended on September 28, 2013 (the “Channel Agreement” and such previous amendment, the “First Amendment”). The Channel Agreement provides for a “channel collaboration” arrangement governing a strategic collaboration for the development and commercialization of autologous fibroblasts and autologous dermal cells, with and without gene therapy, in the United States. The Channel Agreement originally granted the Company an exclusive license to use proprietary technologies and other intellectual property of Intrexon to research, develop, use, import, export, make, have made, sell, and offer for sale certain products in the field in the United States.
	Pursuant to the Channel Agreement and Amendments, the Company engaged Intrexon for support services for the development of new products covered under the Channel Agreement and Amendment, and will reimburse Intrexon for its fully-loaded cost for time and materials for transgenes, cell processing, or other work performed by Intrexon for such research and manufacturing. For the years ended December 31, 2014, 2013 and 2012, the Company incurred expenses of $4.2 million, $3.7 million and $0.1 million, respectively, for work performed.  As of December 31, 2014 and 2013, the Company had outstanding trade payables with Intrexon of $1.0 million and $1.3 million, respectively.  The Company will pay quarterly cash royalties on improved products equal to one-third of cost of goods sold savings less any such savings developed by the Company outside of the Channel Agreement or Amendment. On all other developed products, the Company will pay Intrexon quarterly cash royalties of 7% on aggregate annualized net sales up to $100 million, and 14% on aggregate annualized net sales greater than $100 million. Sales from the Company’s products (including new indications) marketed at the time of the Channel Agreement are not subject to royalty payments unless they are improved upon through the Channel Agreement.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Leases
	On April 6, 2005, the Company entered into a non-cancellable operating lease (the “Lease”) for its office, warehouse and laboratory facilities in Exton, Pennsylvania.  The lease agreement had a term of 8 years.  On February 17, 2012, the Company entered into an amended and restated lease (the “Amended Lease”) for an additional term of 10 years through the year 2023.  The Lease and the Amended Lease provide for rent payments escalating on an annual basis.  In accordance with ASC 840-20 Operating Leases, the Company calculated the total minimum payments under the lease and divided them equally over the life of the lease to account for the lease on a straight-line basis.  The Company has the option to renew the lease for an additional 5 years at fair market value.  Rental expense totaled $1.6 million, $1.5 million and $1.4 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	License Agreements
	On May 3, 2012, the Company entered into an exclusive license agreement with The Regents of the University of California, under which the Company acquired the rights to commercially apply discoveries resulting from the scientific collaboration between the University of California, Los Angeles (“UCLA”) and the Company.  Under the terms of the license agreement, the Company agreed to pay UCLA a non-refundable initial license fee and to pay UCLA an annual license maintenance fee of a percentage of product royalties, and milestone payments based on the Company’s achievement of certain clinical and regulatory related milestones for these rights.  The Company’s ability to meet the milestones is dependent on a number of factors including final approvals by regulatory agencies and the continued enforceability of patent claims.
	On June 13, 2014 the Company entered into two exclusive license agreements with The Regents of the University of California. Pursuant to the first exclusive license agreement (the “BMP2 Agreement”), UCLA granted to the Company an exclusive, sublicensable right and license to use certain patent rights developed in collaboration between UCLA and the Company relating to the use of human skin cells to produce Bone Morphogenetic Protein (BMP2) for use in osteogenic therapies. In consideration of the license granted under the BMP2 Agreement, the Company will pay UCLA a license issue fee, certain one-time milestone payments, a license maintenance fee, earned royalties on net sales of all licensed products (including sales by sublicensees and affiliates) and a percentage of amounts received from sublicensing activities. The Company is subject to minimum annual royalty payments to UCLA beginning after first commercial sale of a licensed product.
	Under the terms of the second of the exclusive license agreements (the “Genomic Stability Agreement”), UCLA granted to the Company an exclusive, sublicensable right and license to use certain patent rights developed in collaboration between UCLA and the Company relating to media that promotes genomic stability in induced pluripotent stem cell cultures for all research and commercialization purposes. In consideration of the license granted under the Genomic Stability Agreement, the Company will pay to UCLA a license issue fee, certain one-time milestone payments, a license maintenance fee, earned royalties on net sales of all licensed products (including sales by affiliates) and a percentage of amounts received from sublicensing activities. The Company is subject to minimum annual royalty payments to UCLA beginning after first commercial sale of a licensed product.
	On May 3, 2012, the Company also entered into a sponsored research agreement with the Massachusetts Institute of Technology (“MIT”).  Research is currently focused on mesenchymal stem cells derived from adult human skin. The agreement is currently scheduled to terminate in June 2015.
	The amounts in the table below assume the foregoing agreements are continued through their respective terms.  The agreements may be terminated at the option of either party.  In such event, the Company’s obligation would be limited to costs through the date of such termination.
	Contractual Obligations
	The following table summarizes the Company’s contractual obligations as of December 31, 2014:
		Payments due by period
	($ in thousands)	Total		2015		2016		2018		2020
						and 2017		and 2019		and thereafter
	License fee obligations(1)	$	950	$	483	$	308	$	106	$	53
	Operating lease obligations(2)	$	11,168	$	1,211	$	2,508	$	2,670	$	4,779
	Total	$	12,118	$	1,694	$	2,816	$	2,776	$	4,832
	(1)Obligations for license agreement with the University of California, Los Angeles (UCLA) and sponsored research agreement with the Massachusetts Institute of Technology (MIT).  The amounts in the table assume the foregoing agreements are continued through their respective terms.  The agreements may be terminated at the option of either party.  In such event, the Company’s obligation would be limited to costs through the date of such termination.
	(2)Operating lease obligations are stated based on the Amended Lease agreement for the office, warehouse and laboratory facilities executed in February 2012.

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	Supplemental Cash Flow Information
	The following table contains additional cash flow information for the years ended:
	($ in thousands)	December 31, 2014		December 31, 2013		December 31, 2012
	Supplemental disclosures of cash flow information:
	Cash paid for interest	$	—	$	—	$	1,885
	Cash paid for income taxes	$	—	$	—	$	—
	Non-cash investing and financing activities:
	Subscription receivable	$	—	$	—	$	2,004
	Conversion of note payable	$	—	$	—	$	2,385
	Issuance of additional warrants	$	—	$	—	$	11,077
	Conversion of preferred stock derivative balance into common stock	$	—	$	—	$	1,350
	Cashless exercise of warrants previously recorded as a liability	$	—	$	298	$	17
	Warrant liability reclassified to equity	$	—	$	—	$	15,048
	Accrued derivative liability	$	—	$	—	$	793

Discontinued_Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations
	On August 31, 2012, the Company sold all of the shares of common stock of Agera held by the Company, which represented 57% of the outstanding common stock of Agera, to Rohto Pharmaceutical Co., Ltd. for approximately $1.0 million. Accordingly, all operating results from continuing operations exclude the results for Agera which are presented as discontinued operations. The Company recorded a gain for the year ended December 31, 2012 of approximately $0.5 million on the sale.
	The financial results of Agera are classified as discontinued operations in the accompanying Consolidated Statement of
	Operations for the year ended December 31, 2012.
	Summary financial information related to discontinued operations is as follows:
	($ in thousands)	Year ended, December 31, 2012
	Product sales	$	516
	Cost of sales	275
	Gross profit	241
	Operating income (loss)	$	27
	Net loss	$	(2	)
	In addition, there were other minimal losses from foreign subsidiaries which were classified as discontinued operations
	for the year ended December 31, 2012.

Quarterly_Financial_Informatio

Quarterly Financial Information (unaudited and restated)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (unaudited and restated)	Quarterly Financial Information (unaudited)
	This table summarizes the unaudited consolidated financial results of operations for the quarters ended (amounts in thousands except per share data):
		March 31,			June 30,			September 30,			December 31,
	2014 Quarter Ended
	Net product sales	$	46		$	58		$	20		$	56
	Cost of sales	793			547			512			460
	Gross loss	(747		)	(489		)	(492		)	(404		)
	Operating expenses	10,253			6,107			5,699			5,763
	Other income (expense)	(3,009		)	4,339			179			2,795
	Net loss	$	(14,009	)	$	(2,257	)	$	(6,012	)	$	(3,372	)
	Basic net loss per share	$	(0.35	)	$	(0.06	)	$	(0.15	)	$	(0.08	)
	Diluted net loss per share	$	(0.35	)	$	(0.09	)	$	(0.17	)	$	(0.09	)
	2013 Quarter Ended
	Net product sales	$	26		$	62		$	68		$	44
	Cost of sales	2,213			2,104			1,792			1,392
	Gross loss	(2,187		)	(2,042		)	(1,724		)	(1,348		)
	Operating expenses	3,721			3,777			11,401			4,303
	Other income (expense)	1,338			(8,818		)	6,520			(91		)
	Net loss	$	(4,570	)	$	(14,637	)	$	(6,605	)	$	(5,742	)
	Basic net loss per share	$	(0.17	)	$	(0.63	)	$	(0.24	)	$	(0.15	)
	Diluted net loss per share	$	(0.18	)	$	(0.63	)	$	(0.31	)	$	(0.15	)

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and notes.  In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows.  Actual results may differ materially from those estimates.
Principles of Consolidation	Principles of Consolidation
	These consolidated financial statements include the accounts of Fibrocell and its wholly owned subsidiaries.  All intercompany accounts and transactions have been eliminated in consolidation.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk
	As of December 31, 2014, the Company maintains its operating cash with one major U.S. domestic bank and the remainder of its cash and cash equivalents as a money market fund with one major global bank.  Federal insurance coverage on our operating cash amounted to $250,000 per depositor at each financial institution, and the Company’s non-interest bearing cash balances may exceed federally insured limits.  The terms of these deposits are on demand to minimize risk.  The Company has not incurred losses related to these deposits.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable are recorded at the invoiced amount, net of related cash discounts, and do not bear interest.  The Company does not have any off-balance sheet exposure related to the Company’s customers.  The Company maintains an allowance for doubtful accounts related to its accounts receivable that have been deemed to have a high risk of collectability.  Management reviews its accounts receivable on a monthly basis to determine if any receivables will potentially be uncollectible.  Management analyzes historical collection trends and changes in its customer payment patterns, customer concentration and creditworthiness when evaluating the adequacy of its allowance for doubtful accounts.  In its overall allowance for doubtful accounts, the Company includes any receivable balances that are determined to be uncollectible.  Based on the information available, management believes the allowance for doubtful accounts is adequate; however, actual write-offs might exceed the recorded allowance.
Inventory	Inventory
	Inventories are determined at the lower of cost or market value, with cost determined under specific identification and on the first-in-first-out method.  Inventories consist of raw materials and work-in-process.
Property and Equipment	Property and Equipment
	Property and equipment is carried at acquisition cost less accumulated depreciation. Depreciation is computed on a straight-line basis over the estimated useful life of the asset. The cost of repairs and maintenance is charged to expense as incurred. As of December 31, 2013, the useful life for all property and equipment was three years, except for leasehold improvements which were depreciated over the remaining lease term or the life of the asset, whichever was shorter. In the first quarter of 2014, the Company adjusted its useful lives to reflect the expected consumption of the economic benefit of these assets as noted in the following table:
	Property and equipment category	Useful life
	Laboratory equipment	6 years
	Computer equipment and software	3 years
	Furniture and fixtures	10 years
	Leasehold improvements	Lesser of remaining lease term or life of asset
	In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) ASC Topic 250 Accounting Changes and Error Corrections, the Company accounted for this change in useful lives as a change in estimate, with prospective application only. The impact of this change in estimate on depreciation expense was immaterial to the results on the Consolidated Statements of Operations.
Intangible Assets	Intangible Assets
	Intangible assets are research and development assets related to the Company’s primary study on azficel-T that was recognized upon emergence from bankruptcy. The portion of the reorganization value which was attributed to identified intangible assets was $6.3 million. Effective January 1, 2012, the Company launched LAVIV® and as a result, the research and development intangible assets related to the Company’s primary study are considered finite-lived intangible assets and are being amortized over 12 years.  For each of the years ended December 31, 2014, 2013 and 2012, amortization expense was approximately $0.6 million.  The Company expects to amortize approximately $0.6 million for each of the next five years.
	Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges.  Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis.  In accordance with Financial Accounting Standards Board Accounting Standard Codification (“ASC”) 360-10-35 Impairment or Disposal of Long-Lived Assets, the Company reviews its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  There was no impairment expense recognized for the years ended December 31, 2014, 2013 or 2012.
Warrant Liability	Warrant Liability
	The Company accounts for stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement.  Stock warrants are accounted for as a derivative in accordance with Accounting Standards Codification 815, Derivatives and Hedging (“ASC 815”) if the stock warrants contain “down-round protection” or other terms that could potentially require “net cash settlement” and therefore, do not meet the scope exception for treatment as a derivative.  Since “down-round protection” is not an input into the calculation of the fair value of the warrants, the warrants cannot be considered indexed to the Company’s own stock which is a requirement for the scope exception as outlined under ASC 815.  Warrant instruments that could potentially require “net cash settlement” in the absence of express language precluding such settlement and those which include “down-round provisions” are initially classified as derivative liabilities at their estimated fair values, regardless of the likelihood that such instruments will ever be settled in cash.  The Company will continue to classify the fair value of the warrants that contain “down-round protection” and “net cash settlement” as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability.  For additional discussion on warrants, see Note 7.
Revenue Recognition	Revenue Recognition
	The Company recognizes revenue over the period LAVIV® is shipped for injection in accordance with ASC 605 Revenue Recognition (“ASC 605”).  In general, ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services rendered, (3) the fee is fixed and determinable and (4) collectability is reasonably assured.  Revenue from the sale of LAVIV® is not recognized until the first shipment for an injection is shipped.
Cost of Sales	Cost of Sales
	Cost of sales includes the costs related to the processing of cells for LAVIV®, including direct and indirect costs. Beginning in 2014, cost of sales is accounted for using a standard cost system which allocates the direct costs associated with the Company’s manufacturing, facility, quality control, and quality assurance operations as well as overhead costs. The principal reason for the relatively small level of revenue as compared to the cost of sales is that the Company changed corporate strategy in late 2013 to de-emphasize sales of LAVIV® into the aesthetic markets, and towards further research and development of the underlying azficel-T process as well as on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs.
Research and Development Expenses	Research and Development Expenses
	Research and development costs are expensed as incurred and include salaries and benefits, costs paid to third party contractors to perform research, conduct clinical trials, develop and manufacture drug materials and delivery devices, and a portion of facilities cost. Research and development costs also include costs to manufacture product for clinical trial use and to develop manufacturing, cell collection and logistical process improvements.
	Clinical trial costs are a significant component of research and development expenses and include costs associated with third party contractors. Invoicing from third party contractors for services performed can lag several months. The Company accrues the costs of services rendered in connection with third party contractor activities based on its estimate of management fees, site management and monitoring costs and data management costs.
Stock-based Compensation	Stock-based Compensation
	The Company accounts for stock-based awards to employees using the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation.  In addition, the Company accounts for stock-based compensation to nonemployees in accordance with the accounting guidance for equity instruments that are issued to other than employees.  The Company uses a Black-Scholes option-pricing model to determine the fair value of each option grant as of the date of grant for expense incurred.  The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, expected stock price volatility and expected life of the options.  Expected stock price volatility is based on historical volatility of the Company’s stock and the stock of the Company’s peer companies.  The risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant.  The expected life for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted.  The Company estimates future forfeitures of options based upon expected forfeiture rates.
Income Taxes	Income Taxes
	An asset and liability approach is used for financial accounting and reporting for income taxes. Deferred income taxes arise from temporary differences between income tax and financial reporting and principally relate to recognition of revenue and expenses in different periods for financial and tax accounting purposes and are measured using currently enacted tax rates and laws.  In addition, a deferred tax asset can be generated by net operating loss (NOLs) carryover.  If it is more likely than not that some portion or all of a deferred tax asset will not be realized, a valuation allowance is recognized.
	In the event the Company is charged interest or penalties related to income tax matters, the Company would record such interest as interest expense and would record such penalties as other expense in the consolidated statements of operations.  No such charges have been incurred by the Company.  For each of the years ended December 31, 2014, 2013 and 2012, the Company had no uncertain tax positions.
	At December 31, 2014, and December 31, 2013, the Company has provided a full valuation allowance for the net deferred tax assets, the large majority of which relates to the future benefit of loss carryovers.  The tax years 2011 through the present remain open to examination by the major taxing jurisdictions to which the Company is subject.
Loss per share data	Loss Per Share Data
	Basic loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during a period.  The diluted loss per share calculation gives effect to dilutive options, warrants, convertible notes, convertible preferred stock, and other potential dilutive common stock including selected restricted shares of common stock outstanding during the period.  Diluted loss per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and warrants, assuming the exercise of all in-the-money stock options and warrants.  Common share equivalents have been excluded where their inclusion would be anti-dilutive.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The carrying values of certain of the Company’s financial instruments, including cash equivalents and accounts payable approximates fair value due to their short maturities.  Warrant liability is also recorded at fair value. The fair values of the Company’s long term obligations are based on assumptions concerning the amount and timing of estimated future cash flows and assumed discount rates reflecting varying degrees of risk.  The carrying values of the Company’s long term obligations approximate their fair values.
New Accounting Pronouncements, Policy	Recently Issued Accounting Pronouncements
	In January 2015, the FASB issued ASU No. 2015-01, "Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items", which eliminates from U.S. GAAP the concept of extraordinary items. The pronouncement is effective for annual reporting periods ending after December 15, 2015 with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, "Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern", which defines management’s responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provided related footnote disclosures. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The adoption of this guidance will require the Company to disclose its evaluation of its ability to continue as a going concern in the footnotes to the financial statements.
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” which supersedes the current revenue recognition requirements under ASC Topic 605, “Revenue Recognition”. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. It also provides a five step approach to achieve this principle. For public entities, the new guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. Based on current operating conditions, the adoption of this guidance does not have a material impact on the Company’s financial statements; however, it may have a material impact in the future.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable	The following table summarizes the changes in the allowance for doubtful accounts receivable for the indicated periods:
			Balance at beginning of year			Additions charged to earnings			Uncollectible receivables written off, net of recoveries			Balance at end of year
	31-Dec-14		5			12			(2	)		17
	31-Dec-13		25			(20	)		—			5
	31-Dec-12		—			25			—			25
Schedule of computation of basic and diluted earnings per share	Basic loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during a period.  The diluted loss per share calculation gives effect to dilutive options, warrants, convertible notes, convertible preferred stock, and other potential dilutive common stock including selected restricted shares of common stock outstanding during the period.  Diluted loss per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and warrants, assuming the exercise of all in-the-money stock options and warrants.  Common share equivalents have been excluded where their inclusion would be anti-dilutive.
		For the Twelve Months Ended December 31,
	($ in thousands except share and per share data)	2014				2013				2012
	Loss per share — Basic:
	Numerator for basic loss per share	$	(25,650	)		$	(31,554	)		$	(12,711	)
	Denominator for basic loss per share	40,789,445				29,830,207				8,965,098
	Basic loss per common share	$	(0.63	)		$	(1.06	)		$	(1.42	)
	Loss per share — Diluted:
	Numerator for basic loss per share	$	(25,650	)		$	(31,554	)		$	(12,711	)
	Adjust: Fair value of dilutive warrants outstanding	2,840				2,270				11,091
	Numerator for diluted loss per share	$	(28,490	)		$	(33,824	)		$	(23,802	)
	Denominator for basic loss per share	40,789,445				29,830,207				8,965,098
	Plus: Incremental shares underlying “in the money” warrants outstanding	179,954				366,409				181,962
	Denominator for diluted loss per share	40,969,399				30,196,616				9,147,060
	Diluted loss per common share	$	(0.70	)		$	(1.12	)		$	(2.60	)
Securities Excluded from Calculation of Weighted-Average Shares Outstanding	The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding, as their effect would be anti-dilutive:
		For the Twelve Months Ended December 31,
		2014			2013			2012
	Shares underlying “out of the money” options outstanding	2,086,450			1,070,720			562,025
	Shares underlying “in the money” options outstanding	—			998,000			—
	Shares underlying “out of the money” warrants outstanding	4,831,352			4,831,352			4,845,352
	Shares underlying “in the money” warrants outstanding	—			—			1,320

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	Inventories consisted of the following as of:
	($ in thousands)	December 31,		December 31,
		2014		2013
	Raw materials	$	357	$	511
	Work-in-process	214		86
	Inventory	$	571	$	597

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property and equipment consisted of the following as of:
	($ in thousands)	December 31,			December 31,
		2014			2013
	Laboratory equipment	$	1,279		$	1,045
	Computer equipment and software	206			179
	Furniture and fixtures	49			15
	Leasehold improvements	772			448
	Construction-in-process	343			749
		2,649			2,436
	Less: Accumulated depreciation	(1,051		)	(735		)
	Property and equipment, net	$	1,598		$	1,701

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses consisted of the following as of:
	($ in thousands)	December 31,		December 31,
		2014		2013
	Accrued professional fees	$	881	$	194
	Accrued compensation	540		40
	Accrued other	254		253
	Accrued expenses	$	1,675	$	487

Warrants_Tables

Warrants (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Outstanding Liability Classified Warrants to Purchase Common Stock	The following table summarizes outstanding liability classified warrants to purchase common stock as of:
		Number of Warrants
		31-Dec-14			31-Dec-13			Exercise				Expiration Dates
								Price
	Issued in Series A, B and D Preferred Stock offering	2,247,118			2,247,118			$	6.25			Oct 2015 - Dec 2016
	Issued in March 2010 financing	393,416			393,416			$	6.25			Mar 1, 2016
	Issued in June 2011 financing	6,113			6,113			$	22.5			Jun 1, 2016
	Issued in August 2011 financing	565,759			565,759			$	18.75			Aug 1, 2016
	Issued to placement agents in August 2011 financing	50,123			50,123			$	13.635			Aug 1, 2016
	Issued in Series B, D and E Preferred Stock offerings	76,120			76,120			$	2.5			Nov 2015 - Dec 2017
	Issued with Convertible Notes	1,125,578			1,125,578			$	2.5			Jun 1, 2018
	Issued in Series E Preferred Stock offering	1,568,823			1,568,823			$	7.5			Dec 1, 2018
	Total	6,033,050			6,033,050
Calculated Aggregate Fair Values and Net Cash Settlement Value	The following table summarizes the calculated aggregate fair values, along with the assumptions utilized in each calculation:
	($ in thousands, except per share data)	December 31,				December 31,				December 31,
		2014				2013				2012
	Calculated aggregate value	11,281				15,216				14,515
	Weighted average exercise price per share of warrant	7.08				7.08				7.04
	Closing price per share of common stock	$	2.59			$	4.06			$	3.75
	Volatility	68		%		70		%		65		%
	Weighted average remaining expected life (years)	2 years, 7 months				3 years, 6 months				4 years, 6 months
	Risk-free interest rate	0.86		%		1.2		%		0.6		%
	Dividend yield	—		%		—		%		—		%

Equity_Tables

Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Activity of Series D and Series E Redeemable Preferred stock	The following table shows the activity of Series D and Series E Redeemable Preferred stock, with a par value of $0.001 per share and a stated value of $25,000 per share:
		Series D		Series E		Total
		Preferred		Preferred
	Balance at December 31, 2011	3,641		—		3,641
	Issuance of Series E Preferred stock	—		9,141		9,141
	Series D and Series E Preferred converted to common stock	(3,641	)	(9,141	)	(12,782	)
	Balance at December 31, 2012	—		—		—
Sold to accredited investors Series E Convertible Preferred Stock in private placement	During May, June and July 2012 the Company sold to accredited investors in a private placement Series E Convertible Preferred Stock as follows:
	Date of financing	# of shares		Net Proceeds			Warrant		# of Warrants
		of Series E		($ in 000’s)			Exercise		Issued
		Preferred					Price
	14-May-12	3,353		$	2,843		$	7.5	590,128
	24-May-12	2,364		2,042			7.5		416,064
	2-Jun-12	945		822			7.5		166,320
	7-Jun-12	1,192		1,037			7.5		209,792
	28-Jun-12	507		441			7.5		89,232
	16-Jul-12	780		679			7.5		137,280
		9,141		$	7,864				1,608,816

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Company's Financial Assets and Liability Measured at Fair Value on a Recurring Basis	The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liability measured at fair value on a recurring basis as of December 31, 2014 and 2013:
		Fair value measurement using
	($ in thousands)	Quoted prices in			Significant		Significant		Total
		active markets			other		unobservable
		(Level 1)			observable		inputs
					inputs (Level 2)		(Level 3)
	Balance at December 31, 2014
	Assets:
	Cash and cash equivalents	$	37,495		$	—	$	—	$	37,495
	Liabilities:
	Warrant liability	$	—		$	—	$	11,286	$	11,286
		Fair value measurement using
	($ in thousands)	Quoted prices in			Significant		Significant		Total
		active markets			other		unobservable
		(Level 1)			observable		inputs
					inputs (Level 2)		(Level 3)
	Balance at December 31, 2013
	Assets:
	Cash and cash equivalents	$	60,033		$	—	$	—	$	60,033
	Liabilities:
	Warrant liability	$	—		$	—	$	15,216	$	15,216
Warrant liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Reconciliation of Warrant Liability Measured at Fair Value on Recurring Basis	The reconciliation of warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows:
	($ in thousands)	Warrant Liability
	Balance at December 31, 2011	$	23,754
	Issuance of additional warrants	6,766
	Exercise of warrants	(11		)
	Extinguishment of debt related to warrants	4,410
	Change in fair value of warrant liability	(20,404		)
	Balance at December 31, 2012	$	14,515
	Exercise of warrants	(352		)
	Cancellation of warrants	(41		)
	Change in fair value of warrant liability	1,094
	Balance at December 31, 2013	$	15,216
	Exercise of warrants	—
	Cancellation of warrants	—
	Change in fair value of warrant liability	(3,930		)
	Balance at December 31, 2014	$	11,286
Derivative Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Reconciliation of Warrant Liability Measured at Fair Value on Recurring Basis	The reconciliation of derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows:
		Derivative
		Liability
	Balance at January 1, 2012	534
	Issuance of additional preferred stock and other	793
	Conversion of preferred stock	(1,350	)
	Change in fair value of derivative liability	23
	Balance at December 31, 2012	—

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock-Based Compensation Expense	Total stock-based compensation expense recognized using the straight-line attribution method in the consolidated statement of operations for the years ended December 31 is as follows:
	($ in thousands)	2014			2013				2012
	Stock option compensation expense for employees and directors	$	1,236		$	1,045			$	1,200
	Equity awards for nonemployees issued for services	3			105				24
	Total stock-based compensation expense	$	1,239		$	1,150			$	1,224
Details of Fair Value Option Award	The fair market value of the stock options at the date of grant was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions for the years ended December 31:
		2014		2013			2012
	Expected life	5 years, 11 months		5 years, 7 months			5 years, 8 months
	Interest rate	1.9	%	1.6	%		1.6	%
	Dividend yield	—		—			—
	Volatility	70	%	71	%		64	%
Summary of Stock Option Activity
		Number of shares		Weighted-				Weighted-		Aggregate
				average				average		intrinsic
				exercise				remaining		value
				price				contractual term
								(in years)
	Outstanding at December 31, 2011	544,340		$	19.25			7 years, 6 months		$	—
	Granted	38,000		$	8.02
	Forfeited	(20,315	)	$	15.48
	Outstanding at December 31, 2012	562,025		$	18.56			7 years		$	—
	Granted	1,532,000		$	4.15
	Forfeited	(25,305	)	$	14.71
	Outstanding at December 31, 2013	2,068,720		$	7.93			8 years, 5 months		$	544
	Granted	348,000		$	4.19
	Expired	(51,637	)	$	21.61
	Forfeited	(278,633	)	$	4.45
	Outstanding at December 31, 2014	2,086,450		$	7.43			7 years, 2 months		$	—
	Exercisable at December 31, 2014	1,100,250		$	10.63			7 years, 2 months		$	—

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense Benefit	The components of the income tax expense/(benefit) related to continuing operations, are as follows:
		Year ended December 31,			Year ended December 31,			Year ended December 31,
	($ in thousands)	2014			2013			2012
	U.S. Federal:
	Current	$	—		$	—		$	—
	Deferred	—			—			(2,068		)
	U.S. State:
	Current	—			—			—
	Deferred	—			—			(432		)
		$	—		$	—		$	(2,500	)
Schedule of Effective Income Tax Rate Reconciliation	The reconciliation between income taxes/(benefit) at the U.S. federal statutory rate and the amount recorded in the accompanying consolidated financial statements is as follows:
		Year ended December 31,			Year ended December 31,			Year ended December 31,
	($ in thousands)	2014			2013			2012
	Tax benefit at U.S. federal statutory rate	$	(8,977	)	$	(11,044	)	$	(5,475	)
	Increase in domestic valuation allowance	11,109			11,626			11,127
	State income taxes/(benefit) before valuation allowance, net of federal benefit	(846		)	(1,026		)	(1,971		)
	Capital loss limitation	—			—			(817		)
	Loss on extinguishment of debt	—			—			1,966
	Derivative revaluation expense	—			—			8
	Warrant revaluation and other finance (income)/expense	(1,375		)	369			(7,141		)
	Other	89			75			(197		)
		$	—		$	—		$	(2,500	)
Schedule of Deferred Tax Assets and Liabilities	The components of the Company’s net deferred tax assets and liabilities at December 31, 2014, 2013 and 2012 are as follows:
	($ in thousands)	31-Dec-14			31-Dec-13			31-Dec-12
	Deferred tax liabilities:
	Intangible assets	$	2,001		$	2,247		$	2,282
	Total deferred tax liabilities	$	2,001		$	2,247		$	2,282
	Deferred tax assets:
	Loss carryforwards	$	63,560		$	54,253		$	49,598
	Capital loss carryforward	841			844			817
	Property and equipment	1,135			1,149			1,327
	License fees	7,055			5,393			—
	Accrued expenses and other	602			412			360
	Stock compensation	2,953			2,698			2,492
	Total deferred tax assets	76,146			64,749			54,594
	Less: valuation allowance	(74,145		)	(62,502		)	(52,312		)
	Total deferred tax assets	$	2,001		$	2,247		$	2,282
	Net deferred tax assets	$	—		$	—		$	—

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Contractual Obligation, Fiscal Year Maturity Schedule	The following table summarizes the Company’s contractual obligations as of December 31, 2014:
		Payments due by period
	($ in thousands)	Total		2015		2016		2018		2020
						and 2017		and 2019		and thereafter
	License fee obligations(1)	$	950	$	483	$	308	$	106	$	53
	Operating lease obligations(2)	$	11,168	$	1,211	$	2,508	$	2,670	$	4,779
	Total	$	12,118	$	1,694	$	2,816	$	2,776	$	4,832
	(1)Obligations for license agreement with the University of California, Los Angeles (UCLA) and sponsored research agreement with the Massachusetts Institute of Technology (MIT).  The amounts in the table assume the foregoing agreements are continued through their respective terms.  The agreements may be terminated at the option of either party.  In such event, the Company’s obligation would be limited to costs through the date of such termination.
	(2)Operating lease obligations are stated based on the Amended Lease agreement for the office, warehouse and laboratory facilities executed in February 2012.

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures	The following table contains additional cash flow information for the years ended:
	($ in thousands)	December 31, 2014		December 31, 2013		December 31, 2012
	Supplemental disclosures of cash flow information:
	Cash paid for interest	$	—	$	—	$	1,885
	Cash paid for income taxes	$	—	$	—	$	—
	Non-cash investing and financing activities:
	Subscription receivable	$	—	$	—	$	2,004
	Conversion of note payable	$	—	$	—	$	2,385
	Issuance of additional warrants	$	—	$	—	$	11,077
	Conversion of preferred stock derivative balance into common stock	$	—	$	—	$	1,350
	Cashless exercise of warrants previously recorded as a liability	$	—	$	298	$	17
	Warrant liability reclassified to equity	$	—	$	—	$	15,048
	Accrued derivative liability	$	—	$	—	$	793

Discontinued_Operations_Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Summary of Financial Information Related to Discontinued Operations	Summary financial information related to discontinued operations is as follows:
	($ in thousands)	Year ended, December 31, 2012
	Product sales	$	516
	Cost of sales	275
	Gross profit	241
	Operating income (loss)	$	27
	Net loss	$	(2	)

Quarterly_Financial_Informatio1

Quarterly Financial Information (unaudited and restated) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Summary of consolidated financial results of operations	This table summarizes the unaudited consolidated financial results of operations for the quarters ended (amounts in thousands except per share data):
		March 31,			June 30,			September 30,			December 31,
	2014 Quarter Ended
	Net product sales	$	46		$	58		$	20		$	56
	Cost of sales	793			547			512			460
	Gross loss	(747		)	(489		)	(492		)	(404		)
	Operating expenses	10,253			6,107			5,699			5,763
	Other income (expense)	(3,009		)	4,339			179			2,795
	Net loss	$	(14,009	)	$	(2,257	)	$	(6,012	)	$	(3,372	)
	Basic net loss per share	$	(0.35	)	$	(0.06	)	$	(0.15	)	$	(0.08	)
	Diluted net loss per share	$	(0.35	)	$	(0.09	)	$	(0.17	)	$	(0.09	)
	2013 Quarter Ended
	Net product sales	$	26		$	62		$	68		$	44
	Cost of sales	2,213			2,104			1,792			1,392
	Gross loss	(2,187		)	(2,042		)	(1,724		)	(1,348		)
	Operating expenses	3,721			3,777			11,401			4,303
	Other income (expense)	1,338			(8,818		)	6,520			(91		)
	Net loss	$	(4,570	)	$	(14,637	)	$	(6,605	)	$	(5,742	)
	Basic net loss per share	$	(0.17	)	$	(0.63	)	$	(0.24	)	$	(0.15	)
	Diluted net loss per share	$	(0.18	)	$	(0.63	)	$	(0.31	)	$	(0.15	)

Business_and_Organization_Deta

Business and Organization (Details Textual)	12 Months Ended
	Dec. 31, 2014	Aug. 31, 2012
	Segment
Organization And Basis Of Presentation [Line Items]
Number of operating segment	1
Agera
Organization And Basis Of Presentation [Line Items]
Owned outstanding shares of Agera		57.00%

Basis_of_Presentation_Details_

Basis of Presentation (Details Textual) (USD $)	0 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Stockholders equity reverse stock split ratio	25
Reverse stock split, description	Company completed a reverse stock split on the basis of one share of common stock for each currently outstanding 25 shares of pre-split common stock.
Research and Development Expense
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Amortization expense		$0.60	$0.60	$0.60
License costs		$0.60	$0.60	$0.60

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details Textual) (USD $)	0 Months Ended	12 Months Ended
	Jan. 01, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Abstract]
Cash, FDIC Insured Amount		$250,000
Intangible assets		4,687,000	5,238,000		6,300,000
Amortization of Intangible Assets		600,000	600,000	600,000
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months		600,000
Finite-Lived Intangible Assets, Amortization Expense, Year Two		600,000
Finite-Lived Intangible Assets, Amortization Expense, Year Three		600,000
Finite-Lived Intangible Assets, Amortization Expense, Year Four		600,000
Finite-Lived Intangible Assets, Amortization Expense, Year Five		600,000
Finite-Lived Intangible Asset, Useful Life	12 years
Asset Impairment Charges		$0	$0	$0

Summary_of_Significant_Account4

Summary of Significant Accounting Policies Allowance for Doubtful Accounting Receivable (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts Receivable [Roll Forward]
Allowance for Doubtful Accounts Receivable, Beginning of the year	$5	$25	$0
Additions charged to earnings	12	-20	25
Uncollectible receivables written off, net of recoveries	-2	0	0
Allowance for Doubtful Accounts Receivable, End of the year	$17	$5	$25

Summary_of_Significant_Account5

Summary of Significant Accounting Policies Summary of Significant Accounting Policies Useful Life (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Asset Impairment Charges	$0	$0	$0
Laboratory equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	6 years	3 years
Computer Equipment And Software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years	3 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years	3 years

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income (loss) per share - Basic:
Net loss	($3,372)	($6,012)	($2,257)	($14,009)	($5,742)	($6,605)	($14,637)	($4,570)	($25,650)	($31,554)	($12,711)
Denominator for basic income (loss) per share (in shares)									40,789,445	29,830,207	8,965,098
Basic income (loss) per common share (in dollars per share)	($0.08)	($0.15)	($0.06)	($0.35)	($0.15)	($0.24)	($0.63)	($0.17)	($0.63)	($1.06)	($1.42)
Income (loss) per share - Diluted:
Net loss	-3,372	-6,012	-2,257	-14,009	-5,742	-6,605	-14,637	-4,570	-25,650	-31,554	-12,711
Adjust: Fair value of dilutive warrants outstanding									2,840	2,270	11,091
Numerator for diluted income (loss) per share (in dollars)									($28,490)	($33,824)	($23,802)
Denominator for basic income (loss) per share (in shares)									40,789,445	29,830,207	8,965,098
Plus: Incremental shares underlying "in the money" warrants outstanding (in shares)									179,954	366,409	181,962
Denominator for diluted income (loss) per share (in shares)									40,969,399	30,196,616	9,147,060
Diluted income (loss) per common share (in dollars per share)	($0.09)	($0.17)	($0.09)	($0.35)	($0.15)	($0.31)	($0.63)	($0.18)	($0.70)	($1.12)	($2.60)

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Details 2)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Shares underlying “out of the money” options outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,086,450	1,070,720	562,025
Shares underlying “in the money” options outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	998,000	0
Shares underlying “out of the money” warrants outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,831,352	4,831,352	4,845,352
Shares underlying “in the money” warrants outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	0	1,320

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$357	$511
Work-in-process	214	86
Inventory	$571	$597

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment, Gross, Total	$2,649	$2,436
Less: Accumulated depreciation	-1,051	-735
Property and equipment, net	1,598	1,701
Laboratory equipment
Property, Plant and Equipment, Gross, Total	1,279	1,045
Computer equipment and software
Property, Plant and Equipment, Gross, Total	206	179
Furniture and fixtures
Property, Plant and Equipment, Gross, Total	49	15
Leasehold improvements
Property, Plant and Equipment, Gross, Total	772	448
Construction-in-process
Property, Plant and Equipment, Gross, Total	$343	$749

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property and Equipment Textual [Abstract]
Depreciation	$0.30	$0.30	$0.30

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Accrued professional fees	$881	$194
Accrued compensation	540	40
Accrued other	254	253
Accrued expenses	$1,675	$487

Warrants_Details

Warrants (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 16, 2012	Jun. 28, 2012	Jun. 07, 2012	Jun. 02, 2012	24-May-12	14-May-12
Maximum
Class of Warrant or Right [Line Items]
Warrant Exercise Price	7.5
Minimum
Class of Warrant or Right [Line Items]
Warrant Exercise Price	6.25
Warrant Liability
Class of Warrant or Right [Line Items]
Warrants issued to purchase common stock	6,033,050	6,033,050
Issued in Series A, B and D Preferred Stock offering | Warrant Liability
Class of Warrant or Right [Line Items]
Warrants issued to purchase common stock	2,247,118	2,247,118
Warrant Exercise Price	6.25
Issued in March 2010 financing | Warrant Liability
Class of Warrant or Right [Line Items]
Warrants issued to purchase common stock	393,416	393,416
Warrant Exercise Price	6.25
Expiration Dates	1-Mar-16
Issued in June 2011 financing | Warrant Liability
Class of Warrant or Right [Line Items]
Warrants issued to purchase common stock	6,113	6,113
Warrant Exercise Price	22.5
Expiration Dates	1-Jun-16
Issued in August 2011 financing | Warrant Liability
Class of Warrant or Right [Line Items]
Warrants issued to purchase common stock	565,759	565,759
Warrant Exercise Price	18.75
Expiration Dates	1-Aug-16
Issued to placement agents in August 2011 financing | Warrant Liability
Class of Warrant or Right [Line Items]
Warrants issued to purchase common stock	50,123	50,123
Warrant Exercise Price	13.635
Expiration Dates	1-Aug-16
Issued in Series B, D and E Preferred Stock offerings | Warrant Liability
Class of Warrant or Right [Line Items]
Warrants issued to purchase common stock	76,120	76,120
Warrant Exercise Price	2.5
Issued with Convertible Notes | Warrant Liability
Class of Warrant or Right [Line Items]
Warrants issued to purchase common stock	1,125,578	1,125,578
Warrant Exercise Price	2.5
Expiration Dates	1-Jun-18
Issued in Series E Preferred Stock offering
Class of Warrant or Right [Line Items]
Warrant Exercise Price			7.5	7.5	7.5	7.5	7.5	7.5
Issued in Series E Preferred Stock offering | Warrant Liability
Class of Warrant or Right [Line Items]
Warrants issued to purchase common stock	1,568,823	1,568,823
Warrant Exercise Price	7.5
Expiration Dates	1-Dec-18

Warrants_Details_1

Warrants (Details 1) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Class of Warrant or Right [Line Items]
Calculated aggregate value	$11,286	$15,216
Warrant Liability
Class of Warrant or Right [Line Items]
Calculated aggregate value	$11,281	$15,216	$14,515
Weighted average exercise price per share of warrant	$7.08	$7.08	$7.04
Closing price per share of common stock	$2.59	$4.06	$3.75
Volatility	68.00%	70.00%	65.00%
Weighted average remaining expected life (years)	2 years 7 months	3 years 6 months	4 years 6 months
Risk-free interest rate	0.86%	1.20%	0.60%
Dividend yield	0.00%	0.00%	0.00%

Warrants_Details_Textual

Warrants (Details Textual) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Warrants exercised	0
Number Of Cashless Warrants Exercised During Period		85,000
Shares Issued During Period Shares Cash Less Warrants Exercised		46,837
Warrant Liability
Change in estimated fair value resulted in non-cash income (expense)	$3.90	($1.10)	$20.40

Debt_Details_Textual

Debt (Details Textual) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 01, 2012	Oct. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Percentage of redemption of principle amount of convertible notes	25.00%
Per share conversion price of convertible notes	$6.25
Notes may accelerated on default on or after date	1-Oct-12
Per share converted price of convertible notes		$6.25
Gains (Losses) on Extinguishment of Debt			$0	$0	($5,617)
Promissory Notes
Debt Instrument, Interest Rate, Stated Percentage	12.50%
Convertible Notes Payable
Debt Instrument, Issuance Date	1-Jun-12
Maturity date of convertible notes one	1-Dec-12
Percentage of interest payable in kind	15.00%
Maturity date of convertible notes two	1-Mar-13
Maturity date of convertible notes three	1-Jun-12
Maturity date of convertible notes four	1-Sep-13
Convertible Notes Payable
Debt Instrument, Interest Rate, Stated Percentage	12.50%
Promissory Notes
Debt Instrument, Interest Rate, Stated Percentage					12.50%
Period of warrant to purchase common share	5 years
Gains (Losses) on Extinguishment of Debt					-5,600
Promissory Notes | Embedded conversion option
Gains (Losses) on Extinguishment of Debt					-1,200
Promissory Notes | Warrants
Gains (Losses) on Extinguishment of Debt					($4,400)

Equity_Details

Equity (Details)	12 Months Ended
	Dec. 31, 2012
Activity of Series D and Series E Redeemable Preferred stock
Preferred stock, beginning balance	3,641
Issuance of Series E Preferred stock	9,141
Series D and Series E Preferred converted to common stock	-12,782
Preferred stock, ending balance	0
Series D Preferred Stock
Activity of Series D and Series E Redeemable Preferred stock
Preferred stock, beginning balance	3,641
Series D and Series E Preferred converted to common stock	-3,641
Preferred stock, ending balance	0
Issued in Series E Preferred Stock offering
Activity of Series D and Series E Redeemable Preferred stock
Preferred stock, beginning balance	0
Issuance of Series E Preferred stock	9,141
Series D and Series E Preferred converted to common stock	-9,141
Preferred stock, ending balance	0

Equity_Details_1

Equity (Details 1) (USD $)	12 Months Ended			0 Months Ended			1 Months Ended	0 Months Ended	1 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 16, 2012	Jun. 02, 2012	Jun. 07, 2012	Jun. 28, 2012	14-May-12	24-May-12
Net Proceeds	$0	$0	$7,864
Issued in Series E Preferred Stock offering
Number of shares of Series E Preferred			9,141	780	945	1,192	507	3,353	2,364
Net Proceeds			$7,864	$679	$822	$1,037	$441	$2,843	$2,042
Warrant Exercise Price				7.5	7.5	7.5	7.5	7.5	7.5
Number of Warrants Issued			1,608,816	137,280	166,320	209,792	89,232	590,128	416,064

Equity_Details_Textual

Equity (Details Textual) (USD $)	0 Months Ended			1 Months Ended	12 Months Ended			1 Months Ended	3 Months Ended
	Jul. 26, 2013	Oct. 09, 2012	Oct. 09, 2012	Oct. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2012	Mar. 31, 2014	Oct. 05, 2012	Jul. 16, 2012	Jun. 28, 2012	Jun. 07, 2012	Jun. 02, 2012	24-May-12	14-May-12
Class of Stock [Line Items]
Allocated To Fair Value Of Warrants					$7,800,000
Equity (Textual) [Abstract]
Aggregate purchase price of the common stock						47,118,000	40,185,000
Payments of Stock Issuance Costs				2,700,000
Fair Value Of Common Stock	6,400,000		6,900,000
Stock Issued During Period Closing Shares	1,243,781		1,317,520
Stock Issued During Period Closing Price Per Share	$5.15		$5.25
Preferred stock, shares authorized					5,000,000
Preferred stock outstanding as of closing of the offering					0	0				0
Number of preferred shares issued					0	0
Measurement of derivative liabilities					0	0	-23,000
Derivative Liability Classified As Equity		1,400,000
Equity (Additional Textual) [Abstract]
Holders of warrants to purchase of common stock					4,209,357	4,209,357
Reclassification of converted notes to equity					2,400,000	2,400,000
Number of trading days							20 days
Minimum
Equity (Textual) [Abstract]
Holders of warrants to purchase of common stock at exercise prices					6.25
Maximum
Equity (Textual) [Abstract]
Holders of warrants to purchase of common stock at exercise prices					7.5
Convertible Debt
Equity (Textual) [Abstract]
Convertible Notes		12.50%	12.50%
Aggregate original principal value of convertible Note										3,500,000
Repayment to Notes holder in cash										1,700,000
Debt instrument expected repayment amount										1,500,000
Debt instrument expected repayment unpaid interest amount										200,000
Principal pay of notes holder										2,100,000
Unpaid interest of notes holder										300,000
Common stock at a conversion price										2.5
Number of shares of common stock to be issued upon the conversion of the notes								861,970
Common Stock
Equity (Textual) [Abstract]
Common stock sold by company under Purchase Agreement						12,311,698	18,203,000
Additional Stock Issued During Period Shares								203,000
Aggregate purchase price of the common stock						12,000	18,000
Subscription receivable								2,000,000
Conversion of notes to common shares							2,021,120	36,671
Proceeds from Issuance Initial Public Offering				42,100,000
Increase In Proceeds From Initial Public Offering				47,100,000
Common shares issued as a result of conversion of Series D preferred shares								104,000
Offering
Equity (Textual) [Abstract]
Common stock sold by company under Purchase Agreement				11,000,000
Additional Stock Issued During Period Shares				1,311,698
Stock Issued During Period Issue Price Per Share				$4.10
Offering | Common Stock
Equity (Textual) [Abstract]
Common stock sold by company under Purchase Agreement								18,000,000
Share Price								2.5
Aggregate purchase price of the common stock				40,200,000
Intrexon Corporation
Equity (Textual) [Abstract]
Stock Issued During Period Closing Shares									1,024,590
Stock Issued During Period Closing Price Per Share									$5.03
Series D Preferred Stock
Equity (Textual) [Abstract]
Par value of preferred stock					$0.00
Stated value of preferred stock					$25,000
Accrued dividends					6.00%	6.00%
Preferred stock automatically converted into common stock										454,560
Issued in Series E Preferred Stock offering
Equity (Textual) [Abstract]
Holders of warrants to purchase of common stock at exercise prices											7.5	7.5	7.5	7.5	7.5	7.5
Par value of preferred stock					$0.00
Stated value of preferred stock					$25,000
Accrued dividends					8.00%	8.00%
Preferred stock automatically converted into common stock										1,462,560
Convertible Note Payable
Equity (Textual) [Abstract]
Measurement of derivative liabilities							100,000
Series D and E Preferred Stock
Equity (Textual) [Abstract]
Preferred stock price for determined number of shares of common stock										6.25
Preferred stock automatically converted into common stock										1,917,120
Received gross proceeds										35,000,000
Research and Development Expense | Intrexon Corporation
Equity (Textual) [Abstract]
Fair Value Of Common Stock									$5,200,000

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Assets
Cash and cash equivalents	$37,495	$60,033	$31,346	$10,799
Liabilities
Warrant liability	11,286	15,216
Quoted prices in active markets (Level 1)
Assets
Cash and cash equivalents	37,495	60,033
Significant unobservable inputs (Level 3)
Liabilities
Warrant liability	$11,286	$15,216

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (Warrants, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	$15,216	$14,515	$23,754
Issuance of additional warrants			6,766
Exercise of warrants	0	-352	-11
Extinguishment of debt			4,410
Cancellation of warrants	0	-41
Change in fair value of warrant liability	-3,930	1,094	-20,404
Ending Balance	$11,286	$15,216	$14,515

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 2) (Derivative Liability, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012
Derivative Liability
Reconciliation of derivative liability measured at fair value on a recurring basis using unobservable
Beginning Balance	$534
Issuance of additional preferred stock and other	793
Conversion of preferred stock	-1,350
Change in fair value of derivative liability	23
Ending Balance	$0

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$1,239	$1,150	$1,224
Shares Underlying Options Outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	1,236	1,045	1,200
Equity Awards for Nonemployees Issued for Services
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$3	$105	$24

ShareBased_Compensation_Detail1

Share-Based Compensation (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected life	5 years 11 months	5 years 7 months	5 years 8 months
Interest rate	1.90%	1.60%	1.60%
Volatility	70.00%	71.00%	64.00%

ShareBased_Compensation_Detail2

Share-Based Compensation (Details 2) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of shares outstanding, Beginning Balance	2,068,720	562,025	544,340
Number of shares, Granted	348,000	1,532,000	38,000
Number of shares, Expired	-51,637
Number of shares, Forfeited	-278,633	-25,305	-20,315
Number of shares outstanding, Ending Balance	2,086,450	2,068,720	562,025	544,340
Number of shares, Exercisable	1,100,250
Weighted-average exercise price, Outstanding, Beginning of Period	$7.93	$18.56	$19.25
Weighted-average exercise price, Granted	$4.19	$4.15	$8.02
Weighted-average exercise price, Expired	$21.61
Weighted-average exercise price, Forfeited	$4.45	$14.71	$15.48
Weighted-average exercise price, Outstanding, End of Period	$7.43	$7.93	$18.56	$19.25
Weighted-average exercise price, Exercisable	$10.63
Weighted-average remaining contractual term (in years), Outstanding	7 years 2 months	8 years 5 months	7 years 0 months	7 years 6 months
Weighted-average remaining contractual term (in years), Exercisable	7 years 2 months
Aggregate intrinsic value, Outstanding, Beginning	$544	$0	$0
Aggregate intrinsic value, Outstanding, Ending	0	544	0	0
Aggregate intrinsic value, Exercisable	$0

ShareBased_Compensation_Detail3

Share-Based Compensation (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award determination	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Fair market value of options granted	$2.64	$2.79	$5
Fair value of shares vested	$1,200,000	$1,200,000	$1,300,000
Options exercises in period	0	0	0
Unrecognized compensation costs, options	2,100,000
Number of nonvested stock options	986,200
Weighted average exercise price of nonvested stock options	$3.86
Intrinsic value of nonvested options	0
Equity Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock reserved	5,600,000
Additional Common Stock Capital Shares Reserved For Future Issuance	206,000
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Options available for grant	3,530,553
Weighted-average period to recognize compensation cost	3 years 9 months 18 days
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	$0

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
U.S. Federal:
Current	$0	$0	$0
Deferred	0	0	-2,068
U.S. State:
Current	0	0	0
Deferred	0	0	-432
Federal Income Tax Expense (Benefit), Continuing Operations, Total	$0	$0	($2,500)

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Tax benefit at U.S. federal statutory rate	($8,977)	($11,044)	($5,475)
Increase in domestic valuation allowance	11,109	11,626	11,127
State income taxes/(benefit) before valuation allowance, net of federal benefit	-846	-1,026	-1,971
Capital loss limitation	0	0	-817
Loss on extinguishment of debt	0	0	1,966
Derivative revaluation expense	0	0	8
Warrant revaluation and other finance (income)/expense	-1,375	369	-7,141
Other	89	75	-197
Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations, Extraordinary Items	$0	$0	($2,500)

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred tax liabilities:
Intangible assets	$2,001	$2,247	$2,282
Total deferred tax liabilities	2,001	2,247	2,282
Deferred tax assets:
Loss carryforwards	63,560	54,253	49,598
Capital loss carryforward	841	844	817
Property and equipment	1,135	1,149	1,327
License fees	7,055	5,393	0
Accrued expenses and other	602	412	360
Stock compensation	2,953	2,698	2,492
Total deferred tax assets	76,146	64,749	54,594
Less: valuation allowance	-74,145	-62,502	-52,312
Total deferred tax assets	2,001	2,247	2,282
Net deferred tax assets	$0	$0	$0

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Loss Carryforwards [Line Items]
Operating loss carryforward expiration year	2018 to 2034
Valuation Allowance, Deferred Tax Asset, Change in Amount	$11.60	$10.20	$11.10
U.S
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	167.5
Non us
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$25.50

Collaboration_with_Related_Par1

Collaboration with Related Party (Details Textual) (Intrexon Corporation, USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Collaboration Agreements [Line Items]
Product development expense	$4.20	$3.70	$0.10
Accounts Payable, Trade, Current	$1	$1.30
Obligations for payments of quarterly cash royalties	On all other developed products, the Company will pay Intrexon quarterly cash royalties of 7% on aggregate annualized net sales up to $100 million, and 14% on aggregate annualized net sales greater than $100 million.
Net Sales Upto Hundred Million
Collaboration Agreements [Line Items]
Royalty percentage	7.00%
Net Sales Greater Than Hundred Million
Collaboration Agreements [Line Items]
Royalty percentage	14.00%

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]
License Fee Obligations, Total	$950	[1]
License Fee Obligations, 2015	483	[1]
License Fee Obligations, 2016 and 2017	308	[1]
License Fee Obligations, 2018 and 2019	106	[1]
License Fee Obligations, 2020 and thereafter	53	[1]
Operating lease obligations, Total	11,168	[2]
Operating lease obligations, 2015	1,211	[2]
Operating lease obligations, 2016 and 2017	2,508	[2]
Operating lease obligations, 2018 and 2019	2,670	[2]
Operating lease obligations, 2020 and thereafter	4,779	[2]
Total	12,118
Total, 2015	1,694
Total, 2016 and 2017	2,816
Total, 2018 and 2019	2,776
Total, 2020 and thereafter	$4,832
[1]	Obligations for license agreement with the University of California, Los Angeles (UCLA) and sponsored research agreement with the Massachusetts Institute of Technology (MIT). The amounts in the table assume the foregoing agreements are continued through their respective terms. The agreements may be terminated at the option of either party. In such event, the Company’s obligation would be limited to costs through the date of such termination.
[2]	Operating lease obligations are stated based on the Amended Lease agreement for the office, warehouse and laboratory facilities executed in February 2012.

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)	0 Months Ended	12 Months Ended			0 Months Ended
In Millions, unless otherwise specified	Apr. 06, 2005	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 17, 2012	3-May-12
Lessor Leasing Arrangements, Operating Leases, Term of Contract	8 years
Lessor Leasing Arrangements, Operating Leases, Renewal Term		5 years
Operating Leases, Rent Expense		$1.60	$1.50	$1.40
Amended Lease [Member]
Lessor Leasing Arrangements, Operating Leases, Term of Contract					10 years
Regents Of University Of California [Member]
Period for payment of initial license fees						30 days
Massachusetts Institute Of Technology [Member]
Agreement Termination Period						June 2015

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information - Summary of Additional Cash Flow Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Supplemental disclosures of cash flow information:
Cash paid for interest	$0	$0	$1,885
Cash paid for income taxes	0	0	0
Non-cash investing and financing activities:
Subscription receivable	0	0	2,004
Conversion of note payable	0	0	2,385
Issuance of additional warrants	0	0	11,077
Conversion of preferred stock derivative balance into common stock	0	0	1,350
Cashless exercise of warrants previously recorded as a liability	0	298	17
Warrant liability reclassified to equity	0	0	15,048
Accrued derivative liability	$0	$0	$793

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net product sales	$56	$20	$58	$46	$44	$68	$62	$26	$180	$200	$153
Cost of sales	460	512	547	793	1,392	1,792	2,104	2,213	2,312	7,501	7,804
Gross Profit	-404	-492	-489	-747	-1,348	-1,724	-2,042	-2,187	-2,132	-7,301	-7,651
Operating income (loss)									-29,954	-30,503	-29,390
Net loss									-25,650	-31,554	-12,687
Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net product sales											516
Cost of sales											275
Gross Profit											241
Operating income (loss)											27
Net loss											($2)

Discontinued_Operations_Detail1

Discontinued Operations (Details Textual) (USD $)	1 Months Ended	12 Months Ended
	Aug. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Closing date of the agreement	31-Aug-12
Selling price	$1,000,000
Discontinued Operation, Gain Loss on Disposal of Discontinued Operation, Net of Tax		$0	$0	$467,000
Agera
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Outstanding common stock of Agera	57.00%

Quarterly_Financial_Informatio2

Quarterly Financial Information (unaudited and restated) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Net product sales	$56	$20	$58	$46	$44	$68	$62	$26	$180	$200	$153
Cost of sales	460	512	547	793	1,392	1,792	2,104	2,213	2,312	7,501	7,804
Gross loss	-404	-492	-489	-747	-1,348	-1,724	-2,042	-2,187	-2,132	-7,301	-7,651
Operating expenses	5,763	5,699	6,107	10,253	4,303	11,401	3,777	3,721
Other income (expense)	2,795	179	4,339	-3,009	-91	6,520	-8,818	1,338
Net loss attributable to Fibrocell Science, Inc. common stockholders	($3,372)	($6,012)	($2,257)	($14,009)	($5,742)	($6,605)	($14,637)	($4,570)	($25,650)	($31,554)	($12,711)
Basic net income (loss) per share (in dollars per share)	($0.08)	($0.15)	($0.06)	($0.35)	($0.15)	($0.24)	($0.63)	($0.17)	($0.63)	($1.06)	($1.42)
Diluted net income (loss) per share (in dollars per share)	($0.09)	($0.17)	($0.09)	($0.35)	($0.15)	($0.31)	($0.63)	($0.18)	($0.70)	($1.12)	($2.60)